[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 89 of about 89
1. Blakeley J, Grossman S: Anaplastic oligodendroglioma. Curr Treat Options Neurol; 2008 Jul;10(4):295-307
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic oligodendroglioma.
  • Although uncommon, anaplastic oligodendrogliomas (AODs) are important to recognize, as they have unique molecular, histologic, and clinical features.
  • Patients with new seizures or new focal neurologic deficits should be referred for brain MRI with contrast.
  • If the MRI suggests a malignant glioma, maximal feasible tumor resection is advised for accurate diagnosis and for relief of tumor-related neurologic symptoms.
  • Unfortunately, AOD remains a terminal brain cancer even with maximal therapies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18579016.001).
  • [ISSN] 1092-8480
  • [Journal-full-title] Current treatment options in neurology
  • [ISO-abbreviation] Curr Treat Options Neurol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS567597; NLM/ PMC3994534
  •  go-up   go-down


2. Kang SG, Kim JH, Nam DH, Park K: Clinical and radiological prognostic factors of anaplastic oligodendroglioma treated by combined therapy. Neurol Med Chir (Tokyo); 2005 May;45(5):232-8; discussion 238-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and radiological prognostic factors of anaplastic oligodendroglioma treated by combined therapy.
  • The clinical and radiological prognostic factors were investigated in 32 patients with newly diagnosed anaplastic oligodendroglioma treated by combined therapy using surgery, postoperative radiation therapy, and adjuvant chemotherapy between September 1994 and December 2002.
  • Median survival was 58 months after diagnosis, and the 5-year survival rate was 49%.
  • [MeSH-major] Brain Neoplasms / radiography. Brain Neoplasms / therapy. Oligodendroglioma / radiography. Oligodendroglioma / therapy

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15914962.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


3. Kumar V, Singh K, Tatke M, Rathi AK, Shekhar S, Bahadur AK: Synchronous anaplastic oligodendroglioma and carcinoma tongue: a rare association. J Cancer Res Ther; 2010 Apr-Jun;6(2):227-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous anaplastic oligodendroglioma and carcinoma tongue: a rare association.
  • We present the case of a 45-year-old female patient who harbored two synchronous primary malignant neoplasms-an anaplastic oligodendroglioma of the right frontal lobe and a squamous cell carcinoma of the tongue.
  • [MeSH-major] Brain Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Neoplasms, Multiple Primary / diagnosis. Oligodendroglioma / diagnosis. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20622375.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


Advertisement
4. Uzuka T, Kakita A, Inenaga C, Takahashi H, Tanaka R, Takahashi H: Frontal anaplastic oligodendroglioma showing multi-organ metastases after a long clinical course. Case report. Neurol Med Chir (Tokyo); 2007 Apr;47(4):174-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frontal anaplastic oligodendroglioma showing multi-organ metastases after a long clinical course. Case report.
  • A 17-year-old woman presented with an anaplastic oligodendroglioma manifesting as generalized seizure.
  • The final diagnosis was anaplastic oligodendroglioma.
  • This rare case of cerebral anaplastic oligodendroglioma developed in adolescence, and rapid hematogenous spread of the glioma cells into the systemic organs occurred after a relatively long clinical course.
  • [MeSH-major] Brain Neoplasms / pathology. Frontal Lobe. Oligodendroglioma / secondary

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17457022.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Levidou G, Korkolopoulou P, Agrogiannis G, Paidakakos N, Bouramas D, Patsouris E: Low-grade oligodendroglioma of the pineal gland: a case report and review of the literature. Diagn Pathol; 2010;5:59
Genetic Alliance. consumer health - Oligodendroglioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade oligodendroglioma of the pineal gland: a case report and review of the literature.
  • BACKGROUND: Gliomas are a very rare subtype of pineal region tumours, whereas oligodendrogliomas of the pineal region are exceedingly rare, since there have been only 3 cases of anaplastic oligodedrogliomas reported this far.
  • METHODS-RESULTS: We present a case of a low-grade oligodendroglioma arising in the pineal gland of a 37 year-old woman.
  • However, the diagnosis of a low grade oligodendroglioma of the pineal gland was assigned.
  • CONCLUSION: Although the spectrum of tumours arising in the pineal gland is broad, the reports of oligodendrogliomas confined to this location are exceedingly rare, and to the best of our knowledge there is no report of a low-grade oligodendroglioma.
  • [MeSH-major] Oligodendroglioma / pathology. Pinealoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 1983 Jul;42(4):391-408 [6864234.001]
  • [Cites] J Morphol. 1982 Jul;173(1):73-86 [7108968.001]
  • [Cites] Surg Neurol. 1985 Feb;23(2):139-42 [3966205.001]
  • [Cites] Hum Pathol. 1995 Jan;26(1):20-30 [7821912.001]
  • [Cites] Surg Neurol. 1995 Jan;43(1):70-5; discussion 75-6 [7701429.001]
  • [Cites] Childs Nerv Syst. 1998 Jan-Feb;14(1-2):53-8 [9548342.001]
  • [Cites] Brain Res. 1999 Sep 25;842(2):359-75 [10526132.001]
  • [Cites] Prog Brain Res. 1965;10:193-217 [14281603.001]
  • [Cites] Cancer. 2005 Apr 25;105(2):80-6 [15662708.001]
  • [Cites] Acta Neuropathol. 2005 Jul;110(1):27-38 [15920661.001]
  • [Cites] Pathol Res Pract. 2006;202(2):85-92 [16413691.001]
  • [Cites] Clin Neuropathol. 2006 Jan-Feb;25(1):18-24 [16465770.001]
  • [Cites] J Neurosurg. 2006 Sep;105(3):461-4 [16961143.001]
  • [Cites] J Neurooncol. 2006 Sep;79(3):307-14 [16645719.001]
  • [Cites] Minim Invasive Neurosurg. 2006 Aug;49(4):247-50 [17041839.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Clin Neuropathol. 2008 May-Jun;27(3):118-28 [18552083.001]
  • [Cites] J Pineal Res. 1984;1(4):323-37 [6545825.001]
  • [Cites] Brain Pathol. 2000 Jan;10(1):49-60 [10668895.001]
  • [Cites] J Neurooncol. 2001 Sep;54(3):239-49 [11767290.001]
  • [Cites] Neurol Med Chir (Tokyo). 2000 May;40(5):283-6 [11980097.001]
  • [Cites] Surg Neurol. 2002 Aug;58(2):111-7; discussion 117 [12453646.001]
  • [Cites] Curr Neurol Neurosci Rep. 2003 May;3(3):223-8 [12691627.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):645-52 [15497117.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):99-103 [7006792.001]
  • [Cites] Pediatrics. 1984 Jul;74(1):97-102 [6739222.001]
  • (PMID = 20849631.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2949720
  •  go-up   go-down


6. Nagy M, Schulz-Ertner D, Bischof M, Welzel T, Hof H, Debus J, Combs SE: Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas. Tumori; 2009 May-Jun;95(3):317-24
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas.
  • PURPOSE: Patients with anaplastic gliomas have a more favorable overall survival than patients with glioblastomas.
  • PATIENTS AND METHODS: Between January 1988 and January 2007, 127 patients with WHO grade III tumors were treated with radiotherapy; the histological classification was pure astrocytoma in 104 patients, oligoastrocytoma in 12 and pure oligodendroglioma in 11 patients.
  • After the primary diagnosis, a biopsy had been performed in 72 patients; subtotal and total resections were performed in 37 and 18 patients, respectively.
  • Median overall survival was 7 months for patients with anaplastic astrocytomas, 44 months for patients with mixed tumors, and 47 months for those with pure oligodendrogliomas.
  • CONCLUSION: Patients with WHO grade III anaplastic astrocytomas, oligodendrogliomas and oligoastrocytomas show favorable overall survival after postoperative radiotherapy compared with glioblastoma patients and should therefore be analyzed separately.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radiotherapy. Glioma / pathology. Glioma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / pathology. Astrocytoma / radiotherapy. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Middle Aged. Oligodendroglioma / pathology. Oligodendroglioma / radiotherapy. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688970.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


7. van den Bent MJ: Anaplastic oligodendroglioma and oligoastrocytoma. Neurol Clin; 2007 Nov;25(4):1089-109, ix-x
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic oligodendroglioma and oligoastrocytoma.
  • Until approximately 15 years ago, the diagnosis of an oligodendroglioma (OD) was merely as a pathologic entity.
  • The only clinical relevant meaning of this histologic diagnosis was the observation that the prognosis of OD was in general better than that of astrocytic tumors of similar grade.
  • Observations have led to the current tendency to consider 1p/19q loss low-grade and anaplastic oligodendroglioma a separate biologic entity, at least within clinical trials, since they have a much better outcome.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Oligodendroglioma / pathology


8. Hyder DJ, Sung L, Pollack IF, Gilles FH, Yates AJ, Davis RL, Boyett JM, Finlay JL: Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience. J Neurooncol; 2007 May;83(1):1-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience.
  • PURPOSE: To review interpathologist diagnosis variability and survival of children treated for either anaplastic mixed glioma (AMG) or anaplastic oligodendroglioma (AO) with surgery, irradiation and chemotherapy.
  • PATIENTS AND METHODS: Two hundred and fifty patients with an institutional diagnosis of malignant glioma were enrolled on Children's Cancer Group CCG-945 between 1985 and 1991, and administered vincristine during involved field radiotherapy, then six cycles of prednisone, lomustine and, vincristine; or two cycles of "eight-drugs-in-one-day" (8-in-1) chemotherapy then involved-field radiotherapy followed by six cycles of 8-in-1 chemotherapy.
  • However, central review established that only nine of 26 children had AMG: either mixed oligoastrocytoma (MOA) or anaplastic mixed oligoastrocytoma (AOA) and only one had AO.
  • CONCLUSION: Diagnosis of these tumors is challenging, with only 35% of institutional diagnoses confirmed for AMG and 25% for AO, and survival among children with these tumors is poor, despite intensive therapy.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / therapy. Glioma / diagnosis. Glioma / therapy. Oligodendroglioma / diagnosis. Oligodendroglioma / therapy
  • [MeSH-minor] Adolescent. Astrocytoma / diagnosis. Astrocytoma / therapy. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Child. Child, Preschool. Cohort Studies. Drug Therapy. Female. Humans. Infant. Male. Neurosurgical Procedures. Radiotherapy. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / therapy. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1998 Jul;89(1):52-9 [9647172.001]
  • [Cites] Hepatology. 1991 Nov;14(5):751-5 [1937381.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1243-52 [12973849.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Oct;56(10):1098-104 [9329453.001]
  • [Cites] Childs Nerv Syst. 1999 Nov;15(11-12):786-8 [10603023.001]
  • [Cites] J Neurooncol. 1994;21(3):255-65 [7699420.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):443-56 [14572971.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):251-5 [12525516.001]
  • [Cites] J Neurosurg. 1995 Apr;82(4):536-47 [7897512.001]
  • [Cites] J Neurooncol. 2003 May;63(1):49-54 [12814254.001]
  • [Cites] J Chronic Dis. 1967 Aug;20(8):637-48 [4860352.001]
  • [Cites] J Neurooncol. 1988;6(1):9-23 [3294353.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):197-207 [12816726.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1238-44; discussion 1244-5 [12015841.001]
  • [Cites] Biometrics. 1977 Mar;33(1):159-74 [843571.001]
  • [Cites] Pediatr Neurosurg. 2003 Sep;39(3):114-21 [12876389.001]
  • [Cites] Curr Treat Options Oncol. 2000 Dec;1(5):459-68 [12057153.001]
  • [Cites] J Neuropathol Exp Neurol. 1994 Nov;53(6):559-71 [7964897.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):420-7 [11832530.001]
  • [Cites] J Acquir Immune Defic Syndr. 1990;3 Suppl 2:S120-3 [2231292.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):91-5 [7815084.001]
  • [Cites] J Neurosurg. 1998 Feb;88(2):215-20 [9452226.001]
  • (PMID = 17252186.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


9. Natale M, Spennato P, Savarese L, Bocchetti A, Esposito S, Barbato R: Anaplastic oligodendroglioma presenting with drop metastases in the cauda equina. Clin Neurol Neurosurg; 2005 Aug;107(5):417-20
Genetic Alliance. consumer health - Oligodendroglioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic oligodendroglioma presenting with drop metastases in the cauda equina.
  • To our knowledge, an intracranial oligodendroglioma presenting with symptoms of drop metastases in the cauda equina has never been reported.
  • A spinal cord MRI showed multiple intradural nodular lesions at the level of the cauda equina, a MRI of the brain showed an intraventricular brain tumor.
  • The histopathological diagnosis of both surgically treated lesions was anaplastic oligodendroglioma.
  • The importance of the clinical and neuroradiological data in the diagnosis is stressed.
  • [MeSH-major] Cauda Equina. Cerebral Ventricle Neoplasms / pathology. Lateral Ventricles. Oligodendroglioma / secondary. Peripheral Nervous System Neoplasms / secondary

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16023538.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


10. Takeuchi Y, Kanamori M, Kumabe T, Saito R, Sonoda Y, Watanabe M, Tominaga T: Collision tumor of anaplastic oligodendroglioma and gangliocytoma: a case report. Brain Tumor Pathol; 2009;26(2):89-93
Hazardous Substances Data Bank. HEMATOXYLIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of anaplastic oligodendroglioma and gangliocytoma: a case report.
  • A 53-year-old woman presented with a rare case of coexistence of anaplastic oligodendroglioma with gangliocytoma manifesting as progressive disturbance of consciousness and left hemiparesis.
  • The former consisted of cells with equal-sized round-to-oval hyperchromatic nuclei and perinuclear halo with microvascular proliferation and necrosis, and the diagnosis was anaplastic oligodendroglioma.
  • The latter consisted of large and dysplastic neurons with marked nucleoli and basophilic cytoplasm containing Nissl bodies, with nonneoplastic glial cells in the stroma, and the diagnosis was gangliocytoma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Ganglioneuroma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Oligodendroglioma / diagnosis. Temporal Lobe / pathology


11. Mut M, Güler-Tezel G, Lopes MB, Bilginer B, Ziyal I, Ozcan OE: Challenging diagnosis: oligodendroglioma versus extraventricular neurocytoma. Clin Neuropathol; 2005 Sep-Oct;24(5):225-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenging diagnosis: oligodendroglioma versus extraventricular neurocytoma.
  • Diagnosis of oligodendroglioma from other clear cell neoplasms of central nervous system (CNS) is still challenging despite advances in neuroradiology and molecular diagnostic tools.
  • Herein, we present a 44-year-old male patient who had a diagnosis of right parietal oligodendroglioma grade II in 1994 which recurred in 2002.
  • Histopathological examination of the recurrent tumor showed anaplastic progression with confusing immunohistochemical (IHC) results; the tumor was positive for NeuN and synaptophysin staining.
  • The question arisen was whether the recurrent tumor was an oligodendroglioma with neuronal differentiation or an extraventricular neurocytoma initially misdiagnosed as oligodendroglioma.
  • Chromosomal analysis revealed 1p/19q deletion, which led to the diagnosis ofanaplastic oligodendroglioma grade III.
  • Accurate diagnosis of oligodendroglioma is crucial due to recent advances and promises in its treatment.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neurocytoma / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Male. Nerve Tissue Proteins / biosynthesis. Synaptophysin / biosynthesis

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167546.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Synaptophysin
  •  go-up   go-down


12. Bruggers C, White K, Zhou H, Chen Z: Extracranial relapse of an anaplastic oligodendroglioma in an adolescent: case report and review of the literature. J Pediatr Hematol Oncol; 2007 May;29(5):319-22
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracranial relapse of an anaplastic oligodendroglioma in an adolescent: case report and review of the literature.
  • Oligodendroglioma is an uncommon childhood tumor and is more chemosensitive than other malignant glial neoplasms.
  • Treatment involves gross total resection, and if anaplastic, radiation and chemotherapy.
  • We report a child with a low-grade oligodendroglioma that recurred as a high-grade oligodendroglioma and ultimately as extraneural systemic relapse.
  • This chemotherapy may be promising in treating malignant oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Oligodendroglioma / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Fatal Outcome. Humans. Magnetic Resonance Imaging / methods. Male. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / therapy. Positron-Emission Tomography / methods. Recurrence

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483710.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Mitsuhashi T, Shimizu Y, Ban S, Ogawa F, Matsutani M, Shimizu M, Hirose T: Anaplastic oligodendroglioma: a case report with characteristic cytologic features, including minigemistocytes. Acta Cytol; 2007 Jul-Aug;51(4):657-60
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic oligodendroglioma: a case report with characteristic cytologic features, including minigemistocytes.
  • BACKGROUND: Absolute criteria for grading oligodendrogliomas are somewhat poorly defined in contrast to those for grading astrocytic tumors, and cytologic features of anaplastic oligodendrogliomas have been poorly described.
  • The diagnosis of anaplastic oligodendroglioma, World Health Organization grade 3, was made, and the results of fluorescence in situ hybridization (chromosome 1q deletion) supported the diagnosis.
  • CONCLUSION: Intraoperative diagnosis of anaplastic oligodendroglioma may not be easy but is possible with judicious consideration of several features: high cellularity, no fibrillary processes, nuclear atypia, pleomorphism, abundant apoptotic cells, occasional mitotic figures, coagulative necrosis, endothelial hyperplasia and characteristic conspicuous minigemistocytes.
  • [MeSH-major] Brain Neoplasms / pathology. Oligodendroglioma / pathology

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17718148.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Hata N, Shono T, Mizoguchi M, Matsumoto K, Guan Y, Nagata S, Hayashi K, Iwaki T, Sasaki T: Loss of heterozygosity analysis in an anaplastic oligodendroglioma arising after radiation therapy. Neurol Res; 2007 Oct;29(7):723-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of heterozygosity analysis in an anaplastic oligodendroglioma arising after radiation therapy.
  • Here, we report a rare case of anaplastic oligodendroglioma arising after radiation therapy, in which genetic analysis was performed.
  • Total removal of the tumor was performed through left frontoparietal craniotomy, and the histologic diagnosis was anaplastic oligodendroglioma.
  • CONCLUSION: The anaplastic oligodendroglioma presented in this report showed a more aggressive clinical course than was expected from the genetic analysis.
  • [MeSH-major] Brain Neoplasms / genetics. Cell Transformation, Neoplastic / genetics. Frontal Lobe / pathology. Loss of Heterozygosity / genetics. Neoplasms, Radiation-Induced / genetics. Oligodendroglioma / genetics. Radiotherapy / adverse effects


15. Hah JO: Anaplastic oligodendroglioma after childhood acute lymphoblastic leukemia: chemotherapy and autologous peripheral blood stem cell transplantation. J Pediatr Hematol Oncol; 2008 Oct;30(10):764-7
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic oligodendroglioma after childhood acute lymphoblastic leukemia: chemotherapy and autologous peripheral blood stem cell transplantation.
  • Secondary brain tumors after cranial irradiation occur in survivors of childhood acute lymphoblastic leukemia (ALL).
  • We report a case of anaplastic oligodendroglioma with recurrence occurring in a 15-year-old girl, 8 years after the diagnosis of ALL.
  • High-dose chemotherapy with stem cell rescue seems to be potentially effective for multiple recurrent anaplastic oligodendroglioma occurring after childhood ALL.
  • [MeSH-major] Neoplasms, Second Primary / therapy. Oligodendroglioma / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications


16. Volavsek M, Lamovec J, Popović M: Extraneural metastases of anaplastic oligodendroglial tumors. Pathol Res Pract; 2009;205(7):502-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraneural metastases of anaplastic oligodendroglial tumors.
  • According to the literature, they tend to appear in glioblastoma patients, but are exceptionally rare in anaplastic oligodendroglioma.
  • We report on an anaplastic oligodendroglioma and an anaplastic oligoastrocytoma that metastasized to cervical lymph nodes and bones.
  • In the second case, metastases to the sacrum and femur developed after surgery for a recurrent anaplastic oligoastrocytoma.
  • Our two cases reconfirm a rare but definite ability not only of glioblastoma but also of anaplastic oligodendroglioma, namely to metastasize to extraneural sites.
  • It is important to bear this in mind, particularly in cases when the history of primary brain tumor is unavailable.
  • In such instances, the correct diagnosis of the metastatic lesion may be extremely difficult if not impossible.
  • [MeSH-major] Astrocytoma / secondary. Brain Neoplasms / pathology. Femoral Neoplasms / secondary. Neoplasm Recurrence, Local. Oligodendroglia / pathology. Oligodendroglioma / secondary. Sacrum / pathology. Spinal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19410385.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Michotte A, Chaskis C, Sadones J, Veld PI, Neyns B: Primary leptomeningeal anaplastic oligodendroglioma with a 1p36-19q13 deletion: report of a unique case successfully treated with Temozolomide. J Neurol Sci; 2009 Dec 15;287(1-2):267-70
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary leptomeningeal anaplastic oligodendroglioma with a 1p36-19q13 deletion: report of a unique case successfully treated with Temozolomide.
  • Primary leptomeningeal oligodendroglioma occurs very rarely and in only one patient a deletion of chromosome 1p has been reported.
  • Brain MRI showed a diffuse right parieto-occipital subarachnoid enhancing lesion without intra-axial extension.
  • The diagnosis of an anaplastic oligodendroglioma (WHO grade 3) was made on pathological examination.
  • To our knowledge this is the first report of a patient with a primary leptomeningeal anaplastic oligodendroglioma with diffuse spinal seeding bearing a 1p36/19q13 deletion.
  • [MeSH-major] Dacarbazine / analogs & derivatives. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / genetics. Mutation / genetics. Oligodendroglioma / drug therapy. Oligodendroglioma / genetics
  • [MeSH-minor] Antineoplastic Agents, Alkylating / administration & dosage. Arachnoid / pathology. Brain / pathology. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Mutational Analysis. Gene Deletion. Genetic Predisposition to Disease / genetics. Genotype. Humans. Magnetic Resonance Imaging. Male. Meningeal Carcinomatosis / drug therapy. Meningeal Carcinomatosis / genetics. Meningeal Carcinomatosis / pathology. Middle Aged. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / genetics. Neoplasm Metastasis / pathology. Pia Mater / pathology. Radiotherapy / methods. Spinal Cord / pathology. Subarachnoid Space / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19751941.001).
  • [ISSN] 1878-5883
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


18. McKinney JS, Steineke T, Nochlin D, Brisman JL: De novo formation of large arteriovenous shunting and a vascular nidus mimicking an arteriovenous malformation within an anaplastic oligodendroglioma: treatment with embolization and resection. J Neurosurg; 2008 Dec;109(6):1098-102
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De novo formation of large arteriovenous shunting and a vascular nidus mimicking an arteriovenous malformation within an anaplastic oligodendroglioma: treatment with embolization and resection.
  • The authors report the de novo occurrence and treatment of an arteriovenous lesion within an anaplastic oligodendroglioma in a patient with previously unremarkable brain imaging.
  • Intracranial arteriovenous malformations (AVMs) are believed to be congenitally acquired lesions, and their association with brain neoplasms is extremely rare.
  • Histological and immunohistochemical testing showed an anaplastic oligodendroglioma mixed with an AVM.
  • To the authors' knowledge this is the first case of de novo occurrence of an arteriovenous lesion with large shunts and a vascular nidus within an anaplastic oligodendroglioma.
  • [MeSH-major] Arteriovenous Fistula / diagnosis. Arteriovenous Fistula / therapy. Brain Neoplasms / blood supply. Embolization, Therapeutic / methods. Intracranial Arteriovenous Malformations / diagnosis. Oligodendroglioma / blood supply
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035725.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Koeller KK, Rushing EJ: From the archives of the AFIP: Oligodendroglioma and its variants: radiologic-pathologic correlation. Radiographics; 2005 Nov-Dec;25(6):1669-88
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From the archives of the AFIP: Oligodendroglioma and its variants: radiologic-pathologic correlation.
  • Oligodendroglioma is the third most common glial neoplasm and most commonly arises in the frontal lobe.
  • Current histopathologic classification schemes recognize two main types of tumors: well-differentiated oligodendroglioma and its anaplastic variant.
  • Less commonly, neoplastic mixtures of both oligodendroglial and astrocytic components occur and are termed oligoastrocytomas, with both well-differentiated and anaplastic forms.
  • [MeSH-major] Brain Neoplasms / diagnosis. Oligodendroglioma / diagnosis

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284142.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 140
  •  go-up   go-down


20. Sega S, Horvat A, Popovic M: Anaplastic oligodendroglioma and gliomatosis type 2 in interferon-beta treated multiple sclerosis patients. Report of two cases. Clin Neurol Neurosurg; 2006 Mar;108(3):259-65
Hazardous Substances Data Bank. Interferon Beta-1b .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic oligodendroglioma and gliomatosis type 2 in interferon-beta treated multiple sclerosis patients. Report of two cases.
  • The concurrence of multiple sclerosis (MS) and brain tumors has been reported, but it is not known whether MS patients are at greater risk of harbouring the latter.
  • The most common cerebral neoplasms reported in MS patients were oligodendroglioma, astrocytoma, glioblastoma and gliomatosis.
  • MS can also present as a mass lesion that mimics a brain tumor.
  • To establish the correct diagnosis radiological follow-up and/or histological confirmation is needed.
  • Two cases of coincidental MS and brain tumors are reviewed.
  • One is a 26-year-old woman with relapsing-remitting MS and an anaplastic oligodendroglioma, the other a 49-year-old woman patient with relapsing-remitting MS and gliomatosis type 2.
  • The concurrence of MS and brain tumors could be purely coincidental, or the result of neoplastic transformation of reactive glial cells in the areas of demyelination.
  • The combination of a brain tumor and MS, and interferon-beta treatment could also be pure coincidence or an unknown side effect of treatment.
  • [MeSH-major] Brain Neoplasms / complications. Glioblastoma / complications. Multiple Sclerosis, Relapsing-Remitting / complications. Oligodendroglioma / complications


21. Da Fonseca CO, Masini M, Futuro D, Caetano R, Gattass CR, Quirico-Santos T: Anaplastic oligodendroglioma responding favorably to intranasal delivery of perillyl alcohol: a case report and literature review. Surg Neurol; 2006 Dec;66(6):611-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic oligodendroglioma responding favorably to intranasal delivery of perillyl alcohol: a case report and literature review.
  • To explore therapeutic strategies and evaluate the clinical results, we report a case of a patient with anaplastic oligodendroglioma managed with intranasal delivery of POH.
  • A contrast-enhanced MRI scan of the brain revealed a regular space-occupying lesion in the right frontal lobe that enhanced with gadolinium.
  • A radical surgical excision of the tumor was carried out, and the histopathological diagnosis was an anaplastic oligodendroglioma.
  • CONCLUSION: Whereas surgery continues to be the primary treatment for oligodendroglioma, the scheme for postoperative therapy has shifted primarily because of the lesion's relative chemosensitivity.
  • This article evaluates the effects of intranasal delivery of POH in a case of regression of anaplastic oligodendroglioma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Frontal Lobe / pathology. Monoterpenes / therapeutic use. Oligodendroglioma / drug therapy. Oligodendroglioma / pathology


22. Ng WH, Lim TC, Tan KK: Disseminated spread of recurrent oligodendroglioma (WHO grade II). J Clin Neurosci; 2006 Jun;13(5):602-7
Genetic Alliance. consumer health - Oligodendroglioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated spread of recurrent oligodendroglioma (WHO grade II).
  • Oligodendroglioma is a relatively uncommon primary brain tumour.
  • The occurrence of metastatic dissemination of oligodendroglioma is rare and usually occurs in patients with anaplastic oligodendroglioma.
  • The dissemination of WHO Grade II oligodendroglioma can occur and we report a patient with an initial diagnosis of a left temporal oligodendroglioma who presented with disseminated disease in the left temporal lobe, sellar region, medulla oblongata, both frontal lobes and ventricles more than 8 years later.
  • Histology at dissemination showed anaplastic oligodendroglioma.
  • Similar reports of metastatic dissemination of oligodendrogliomas reveal that the tumours may remain as WHO Grade II or may progress to anaplastic oligodendroglioma at metastasis.
  • However, regardless of the histological grade at metastasis, the prognosis of metastatic oligodendroglioma is poor.
  • [MeSH-major] Neoplasms, Second Primary / radiography. Oligodendroglioma / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16697645.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Scotland
  • [Number-of-references] 31
  •  go-up   go-down


23. Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol; 2006 Jun 20;24(18):2707-14
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
  • PURPOSE: Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are treated with surgery and radiotherapy (RT) at diagnosis, but they also respond to procarbazine, lomustine, and vincristine (PCV), raising the possibility that early chemotherapy will improve survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Oligodendroglioma / drug therapy. Oligodendroglioma / radiotherapy


24. Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, Figarella-Branger D, Giangaspero F, Giannini C, Mokhtari K, Mørk SJ, Paetau A, Reifenberger G, van den Bent MJ: Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol; 2007 Jun;66(6):545-51
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome.
  • The diagnosis of anaplastic oligodendroglioma (AOD) or anaplastic oligoastrocytoma (AOA) is subject to interobserver variation.
  • The aim of this study was to estimate consensus in typing and grading of these tumors using tumor material collected in a large prospective randomized phase III study and to correlate the consensus diagnosis with the 1p/19q status of the tumors and the clinical outcome.
  • The panel reached consensus on the diagnosis of AOD in 52% of the tumors that had been diagnosed as AOD by the local pathologists, whereas only 8% of the local diagnosis of AOA was confirmed with consensus.
  • The concordance on the panel diagnosis of AOD was high (intraclass correlation = 86%).
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Gene Deletion. Oligodendroglioma / genetics. Oligodendroglioma / pathology


25. Inagawa H, Ishizawa K, Hirose T: Qualitative and quantitative analysis of cytologic assessment of astrocytoma, oligodendroglioma and oligoastrocytoma. Acta Cytol; 2007 Nov-Dec;51(6):900-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Qualitative and quantitative analysis of cytologic assessment of astrocytoma, oligodendroglioma and oligoastrocytoma.
  • OBJECTIVE: To evaluate the usefulness of intraoperative cytology for differential diagnoses of astrocytoma, oligodendroglioma and oligoastrocytoma.
  • STUDY DESIGN: Qualitative analysis of cytologic features of the 3 brain tumors was conducted using intraoperative touch or squash preparations that were stained with the Papanicolaou method, targeting the cellular density, cytoplasmic and nuclear profiles and blood vessel morphology.
  • In both tumors of a higher grade, anaplastic large nuclei and proliferating endothelial cells were noted.
  • CONCLUSION; Cytologic evaluation using touch or squash preparations is of great help for intraoperative differential diagnosis of astrocytoma, oligodendroglioma and oligoastrocytoma.
  • Cytologic as well as histologic assessment should be conducted at the intraoperative diagnosis of these tumors.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Cytodiagnosis / methods. Oligodendroglioma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Count. Cell Nucleus / pathology. Child. Child, Preschool. Cytoplasm / pathology. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted. Intraoperative Period. Male. Middle Aged


26. Mittelbronn M, Wolff M, Bültmann E, Nägele T, Capper D, Beck R, Meyermann R, Beschorner R: Disseminating anaplastic brainstem oligodendroglioma associated with allelic loss in the tumor suppressor candidate region D19S246 of chromosome 19 mimicking an inflammatory central nervous system disease in a 9-year-old boy. Hum Pathol; 2005 Jul;36(7):854-7
Genetic Alliance. consumer health - Oligodendroglioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminating anaplastic brainstem oligodendroglioma associated with allelic loss in the tumor suppressor candidate region D19S246 of chromosome 19 mimicking an inflammatory central nervous system disease in a 9-year-old boy.
  • Magnetic resonance imaging showed brainstem enlargement leading to the diagnosis of an inflammatory process.
  • In addition, the clinical picture, a monocytic cerebrospinal fluid pleocytosis with elevated protein and lactate and serum IgM antibodies to Mycoplasma pneumoniae favored this diagnosis.
  • However, 2 months later, fulminant disease progression led to brain death.
  • The autopsy revealed brain swelling and brainstem softening with a superficial gelatinous mass extending along the spinal cord.
  • Finally, a disseminating anaplastic oligodendroglioma with allelic loss of the D19S246 tumor suppressor candidate locus of chromosome 19 was diagnosed.
  • To our knowledge, this is the first case of a disseminating anaplastic brainstem oligodendroglioma associated with this specific allelic loss occurring in childhood.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Chromosomes, Human, Pair 19. Genes, Tumor Suppressor. Loss of Heterozygosity / genetics. Meningoencephalitis / diagnosis. Oligodendroglioma / diagnosis
  • [MeSH-minor] Brain Stem / pathology. Child. Diagnosis, Differential. Fatal Outcome. Glucocorticoids / therapeutic use. Humans. Injections, Intravenous. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Chromosome 9.
  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16084959.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids
  •  go-up   go-down


27. Takeuchi H, Kubota T, Kitai R, Matsuda K, Hashimoto N, Sato K: Chromosome 1p and 19q deletions in malignant glioneuronal tumors with oligodendroglioma-like component. J Neurooncol; 2009 Jan;91(1):33-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosome 1p and 19q deletions in malignant glioneuronal tumors with oligodendroglioma-like component.
  • We encountered seven cases of MGNT with oligodendroglioma-like component and investigated alternations of chromosome 1p and 19q in these tumors.
  • Histologically, these tumors resembled anaplastic oligodendroglioma.
  • It is inappropriate to make a diagnosis of oligodendroglioma based only on morphological resemblance to oligodendroglia.
  • [MeSH-major] Brain Neoplasms / metabolism. Chromosome Deletion. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Oligodendroglioma / metabolism

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):275-81 [7522542.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):863-71 [11556543.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Aug;24(4):302-8 [9775396.001]
  • [Cites] J Histochem Cytochem. 1996 Oct;44(10):1167-71 [8813082.001]
  • [Cites] Brain Dev. 1998 Mar;20(2):88-94 [9545178.001]
  • [Cites] Hum Pathol. 2004 Sep;35(9):1156-9 [15343519.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10 ):1171-83 [9777979.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):37-59 [9210052.001]
  • [Cites] Histopathology. 2006 Mar;48(4):438-44 [16487366.001]
  • [Cites] Glycoconj J. 1996 Jun;13(3):433-43 [8781974.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1252-60 [11688459.001]
  • [Cites] Int J Cancer. 1995 Jun 22;64(3):207-10 [7622310.001]
  • [Cites] Neurosurgery. 2004 Dec;55(6):1377-91: discussion 1391-2 [15574220.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Neurosurg. 2000 Jun;92(6):983-90 [10839259.001]
  • [Cites] Am J Surg Pathol. 1997 Feb;21(2):206-12 [9042288.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Adv Anat Pathol. 2001 Jul;8(4):183-99 [11444508.001]
  • [Cites] Acta Neuropathol. 2001 Apr;101(4):311-20 [11355302.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Aug;31(4):429-38 [16008827.001]
  • [Cites] Acta Neuropathol. 1986;72(1):15-22 [2435103.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1204-12 [2205356.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Nov;61(11):947-55 [12430711.001]
  • [Cites] J Clin Neurosci. 1998 Oct;5(4):466-9 [18639083.001]
  • [Cites] Acta Neuropathol. 1998 May;95(5):493-504 [9600596.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):91-5 [7815084.001]
  • (PMID = 18781279.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Nerve Tissue Proteins
  •  go-up   go-down


28. Gupta M, Djalilvand A, Brat DJ: Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma. Am J Clin Pathol; 2005 Nov;124(5):755-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma.
  • Diffuse gliomas are the most common brain tumors and include astrocytomas, oligodendrogliomas, and oligoastrocytomas.
  • Their correct pathologic diagnosis requires the ability to distinguish astrocytic from oligodendroglial differentiation in histologic sections, a challenging feat even for the most experienced neuropathologist.
  • Interobserver variability in the diagnosis of diffuse gliomas has been high owing to subjective diagnostic criteria, overlapping morphologic features, and variations in training and practice among pathologists.
  • A select, albeit imperfect, group of molecular and immunohistochemical tests are available to assist in diagnosis of these lesions.
  • Detection of amplified epidermal growth factor receptor favors the diagnosis of high-grade astrocytomas over anaplastic oligodendroglioma, which is especially relevant for small cell astrocytomas.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Oligodendroglioma / pathology


29. Salomão JF, Pone MV, da Silva AR, Leibinger RD, Bellas AR, Campos JM, Garrido JR, Vanazzi E, de Barros AC, Pone SM, Boechat MB: Positive reaction for cysticercosis and multicentric anaplastic oligoastrocytoma. Childs Nerv Syst; 2006 Feb;22(2):182-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive reaction for cysticercosis and multicentric anaplastic oligoastrocytoma.
  • INTRODUCTION: An unusual case of positive immunological testing for cysticercosis in the cystic fluid obtained from an anaplastic oligoastrocytoma is presented.
  • CASE REPORT: A 15-year-old boy was admitted with multiple brain lesions.
  • As the patient deteriorated the cystic lesion was removed and the diagnosis of anaplastic oligoastrocytoma was established.
  • A second lesion was eventually approached and the histopathological diagnosis of both specimens concurred.
  • DISCUSSION: Although some authors believe that chronic inflammatory changes following neurocysticercosis could induce the formation of brain tumors, this association may be a mere coincidence.
  • [MeSH-major] Brain Neoplasms / complications. Cysticercosis / complications. Oligodendroglioma / complications

  • Genetic Alliance. consumer health - Cysticercosis.
  • Genetic Alliance. consumer health - Anaplastic Oligoastrocytoma.
  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Neurol. 1997 Sep;54(9):1125-8 [9311356.001]
  • [Cites] Minim Invasive Neurosurg. 2000 Mar;43(1):51-2 [10794567.001]
  • [Cites] Ann Neurol. 1999 May;45(5):659-62 [10319890.001]
  • [Cites] Childs Nerv Syst. 2003 Dec;19(12):837-40 [14566419.001]
  • [Cites] Neurol India. 2000 Dec;48(4):365-9 [11146603.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Mar;74(3):359-61 [12588927.001]
  • [Cites] Neurology. 1968 Mar;18(3):306 [4968467.001]
  • [Cites] Surg Neurol. 1999 May;51(5):554-7; discussion 557-8 [10321888.001]
  • [Cites] Arq Neuropsiquiatr. 1992 Jun;50(2):234-8 [1308398.001]
  • [Cites] Arch Med Res. 1999 Mar-Apr;30(2):154-8 [10372452.001]
  • [Cites] Neurology. 1997 May;48(5):1330-3 [9153467.001]
  • [Cites] Childs Nerv Syst. 2001 Jan;17 (1-2):101-5 [11219614.001]
  • [Cites] Rev Neurol (Paris). 1987;143(12):844-9 [3438641.001]
  • (PMID = 15778869.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


30. Kojima H, Mori K, Fukudome N, Iseki M, Shimizu S: Cytologic characteristics of intracytoplasmic refractile eosinophilic granular bodies in anaplastic oligodendroglioma: a case report. Acta Cytol; 2008 Jul-Aug;52(4):467-70
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic characteristics of intracytoplasmic refractile eosinophilic granular bodies in anaplastic oligodendroglioma: a case report.
  • BACKGROUND: Oligodendrogliomas, which have a relatively better prognosis than tumors of the astrocytic lineage, have few morphologic clues for diagnosis.
  • CASE: To address this problem, eosinophilic refractile inclusions were examined cytologically in the tumor of a 59-year-old man, using surgical materials for rapid diagnosis.
  • [MeSH-major] Brain Neoplasms / pathology. Cytoplasmic Granules / pathology. Eosinophils / pathology. Inclusion Bodies / pathology. Neoplasm Recurrence, Local. Occipital Lobe / pathology. Oligodendroglioma / pathology

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18702367.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Smith SF, Simpson JM, Sekhon LH: What progress has been made in surgical management of patients with astrocytoma and oligodendroglioma in Australia over the last two decades? J Clin Neurosci; 2005 Nov;12(8):915-20; discussion 921
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What progress has been made in surgical management of patients with astrocytoma and oligodendroglioma in Australia over the last two decades?
  • BACKGROUND: Most primary brain cancers are associated with a dismal prognosis because of their aggressive behaviour and high mortality.
  • OBJECTIVE: To determine changes since 1977 in demographic characteristics, tumour frequencies, surgical management, morbidity and survival for 1,339 patients discharged with astrocytoma (A) and oligodendroglioma (O), which comprise the majority of primary brain cancers, recorded prospectively in northern Sydney neurosurgery databases.
  • Of 144 re-biopsies, 16% had less anaplastic pathology, 54% the same and 30% more anaplastic pathology than the first biopsy.
  • Sex and era of diagnosis did not influence survival.
  • After adjustment for age using proportional hazards regression, survival improved only for anaplastic A, with a 60% improvement for patients diagnosed in era 3, and a 50% improvement for patients diagnosed in era 4 relative to those in era 1.
  • CONCLUSIONS: Although markers of inpatient care have improved since the 1980s, age-adjusted survival has not increased except for patients with anaplastic A.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Neurosurgical Procedures / statistics & numerical data. Oligodendroglioma / surgery. Postoperative Complications

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16326271.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  •  go-up   go-down


32. Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T: Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol; 2006 Sep;79(2):153-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial.
  • PURPOSE: Chemotherapy with alkylating agents is of proven efficacy in recurrent anaplastic oligodendroglioma (AO) with reported response rates ranging between 50% and 70%.
  • PATIENTS AND METHODS: Twenty patients with a median age of 47 (range: 26-65) received a median of 14 (range: 3-24) cycles of TMZ as their first modality of therapy following diagnosis of AO.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Oligodendroglioma / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Expert Opin Pharmacother. 2004 Feb;5(2):295-306 [14996626.001]
  • [Cites] J Neurooncol. 2003 Nov;65(2):127-34 [14686732.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2449-55 [11331324.001]
  • [Cites] Neurology. 1998 Oct;51(4):1140-5 [9781544.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Neurology. 2004 May 25;62(10 ):1783-7 [15159478.001]
  • [Cites] Recent Results Cancer Res. 1994;135:127-33 [8047688.001]
  • [Cites] Ann Oncol. 2003 Apr;14 (4):599-602 [12649108.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):645-52 [15497117.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • (PMID = 16855865.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  •  go-up   go-down


33. Yang LS, Huang FP, Zheng K, Zhang HS, Zhou X, Bao XH, Zheng JJ, Chang C, Zhou LF: Factors affecting prognosis of patients with intracranial anaplastic oligodendrogliomas: a single institutional review of 70 patients. J Neurooncol; 2010 Oct;100(1):113-20
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting prognosis of patients with intracranial anaplastic oligodendrogliomas: a single institutional review of 70 patients.
  • Anaplastic oligodendroglioma (AO) is an uncommon intracranial tumor and prognosis is poor.
  • [MeSH-major] Brain Neoplasms / diagnosis. Oligodendroglioma / diagnosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 2002 Aug;58(2):111-7; discussion 117 [12453646.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Oncology. 2003;65(3):259-66 [14657600.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1279-91; discussion 191 [10598694.001]
  • [Cites] Neurosurgery. 1994 Jun;34(6):959-66; discussion 966 [8084406.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Am J Clin Oncol. 2000 Apr;23(2):170-5 [10776979.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):443-56 [14572971.001]
  • [Cites] Chin Med J (Engl). 2008 Jun 20;121(12):1072-5 [18706219.001]
  • [Cites] Neurology. 2004 May 25;62(10 ):1783-7 [15159478.001]
  • [Cites] J Neurooncol. 2002 Sep;59(3):231-7 [12241120.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Jun;66(6):545-51 [17549014.001]
  • [Cites] Cancer. 1987 Apr 1;59(7):1345-52 [3545437.001]
  • [Cites] J Neurooncol. 2006 Sep;79(2):153-7 [16855865.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Nov;62(11):1118-28 [14656070.001]
  • [Cites] J Neurooncol. 2006 Sep;79(2):159-68 [16821091.001]
  • [Cites] J Neurooncol. 2005 Nov;75(2):189-93 [16132506.001]
  • [Cites] Oncogene. 2002 Jun 6;21(25):3961-8 [12037678.001]
  • (PMID = 20195700.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


34. Kouwenhoven MC, Gorlia T, Kros JM, Ibdaih A, Brandes AA, Bromberg JE, Mokhtari K, van Duinen SG, Teepen JL, Wesseling P, Vandenbos F, Grisold W, Sipos L, Mirimanoff R, Vecht CJ, Allgeier A, Lacombe D, van den Bent MJ: Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro Oncol; 2009 Dec;11(6):737-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
  • Recent studies have shown that the clinical outcome of anaplastic oligodendroglial tumors is variable, but also that the histological diagnosis is subject to interobserver variation.
  • We investigated whether the assessment of 1p/19q codeletion, polysomy of chromosome 7, epidermal growth factor receptor (EGFR) gene amplification (EGFR(amp)), and loss of chromosome 10 or 10q offers additional prognostic information to the histological diagnosis and would allow molecular subtyping.
  • For this study, we used the clinical data and tumor samples of the patients included in multicenter prospective phase III European Organisation for Research and Treatment of Cancer (EORTC) study 26951 on the effects of adjuvant procarbazine, chloroethyl cyclohexylnitrosourea (lomustine), and vincristine chemotherapy in anaplastic oligodendroglial tumors.
  • Three different analyses were performed: on all included patients based on local pathology diagnosis, on the patients with confirmed anaplastic oligodendroglial tumors on central pathology review, and on this latter group but after excluding anaplastic oligoastrocytoma (AOA) with necrosis.
  • In 257 of 368 patients, central pathology review confirmed the presence of an anaplastic oligodendroglial tumor.
  • Tumors with combined 1p and 19q loss (1p(loss)19q(loss)) were histopathologically diagnosed as anaplastic oligodendroglioma, were more frequently located in the frontal lobe, and had a better outcome.
  • Anaplastic oligodendroglial tumors with EGFR(amp) were more frequently AOA, were more often localized outside the frontal lobe, and had a survival similar to that for GBM.
  • In univariate analyses, all molecular factors except loss of 10q were of prognostic significance, but on multivariate analysis a histopathological diagnosis of AOA, necrosis, and 1p(loss)19q(loss) remained independent prognostic factors.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 2000 May;119(1):42-7 [10812170.001]
  • [Cites] Neuropathology. 2008 Aug;28(4):440-3 [18312547.001]
  • [Cites] J Pathol. 2001 May;194(1):81-7 [11329145.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):863-71 [11556543.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6713-5 [11559541.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Nov;60(11):1099-104 [11706939.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):313-9 [12107116.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1276-84 [12599236.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Neurology. 1998 Oct;51(4):1140-5 [9781544.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Jun;58(6):606-12 [10374751.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2318-26 [15470710.001]
  • [Cites] Neurology. 2004 Dec 28;63(12):2360-2 [15623700.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Ann Neurol. 2005 Sep;58(3):483-7 [16130103.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):695-703 [15936158.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2563-9 [16735709.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] J Neurooncol. 2006 Oct;80(1):75-82 [16794749.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2499-503 [16914310.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5419-26 [17135643.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Jun;66(6):545-51 [17549014.001]
  • [Cites] J Neurooncol. 2007 Sep;84(3):279-86 [17431544.001]
  • [Cites] Oncogene. 2008 Mar 27;27(14):2097-108 [17934521.001]
  • [Cites] Brain Pathol. 2008 Jul;18(3):360-9 [18371182.001]
  • [Cites] Neuro Oncol. 2000 Jul;2(3):164-73 [11302337.001]
  • (PMID = 19224764.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / 2U10CA11488-25; United States / NCI NIH HHS / CA / 2U10CA11488-35
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
  • [Other-IDs] NLM/ PMC2802394
  •  go-up   go-down


35. Tanriover N, Ulu MO, Sar M, Uzan M: Anaplastic oligoastrocytoma: previous treatment as a possible cause in a child with acute lymphoblastic leukemia. Childs Nerv Syst; 2007 Apr;23(4):469-73
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic oligoastrocytoma: previous treatment as a possible cause in a child with acute lymphoblastic leukemia.
  • INTRODUCTION: The authors present a 14-year-old patient who developed an anaplastic oligoastrocytoma of the left parietal lobe 9 years after a successful treatment of acute lymphoblastic leukemia (ALL).
  • He had a history of induction chemotherapy, intrathecal methotrexate and prophylactic whole brain irradiation (1,800 cGy in 10 fractions over 2 weeks).
  • DISCUSSION: Radiation-induced neoplasia is suggested to be the late complication of ALL treatment, and evaluation of large clinical series revealed a relationship between young age at ALL diagnosis (<6 years) and increased high-grade glioma occurrence risk.
  • CONCLUSION: The authors have reviewed previously reported cases of secondary central nervous system malignancies focusing on age at ALL diagnosis, and they think that synergistic action of therapeutic modalities could have played a role in the oncogenetic process.
  • [MeSH-major] Brain Neoplasms / etiology. Oligodendroglioma / etiology. Radiotherapy / adverse effects


36. Woodworth G, McGirt MJ, Samdani A, Garonzik I, Olivi A, Weingart JD: Accuracy of frameless and frame-based image-guided stereotactic brain biopsy in the diagnosis of glioma: comparison of biopsy and open resection specimen. Neurol Res; 2005 Jun;27(4):358-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of frameless and frame-based image-guided stereotactic brain biopsy in the diagnosis of glioma: comparison of biopsy and open resection specimen.
  • OBJECTIVES: Tissue heterogeneity and rapid tumor progression may decrease the accuracy a prognostic value of stereotactic brain biopsy in the diagnosis of gliomas.
  • There has been a dramatic increase in the utilization of frameless image-guided stereotactic brain biopsy; however, its accuracy in the diagnosis of glioma remains unstudied.
  • METHODS: The diagnoses of 21 astrocytic brain tumors were derived using image-guided stereotactic biopsy (12 frame-based, nine frameless) and followed by open resection of the lesion 1.5 (0.5-4) months later.
  • The histologic diagnoses yielded by the biopsy were compared with subsequent histologic diagnosis from open tumor resection.
  • Anaplastic oligodendroglioma (ODG) was under-graded as low-grade ODG in one (5%) case.
  • DISCUSSION: Both frameless and frame-based MRI-guided stereotactic brain biopsy are safe and accurately represent the larger glioma mass sufficiently to guide subsequent therapy.
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology. Magnetic Resonance Imaging. Stereotaxic Techniques

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15949232.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Kim L, Glantz M: Chemotherapeutic options for primary brain tumors. Curr Treat Options Oncol; 2006 Nov;7(6):467-78
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapeutic options for primary brain tumors.
  • Malignant gliomas are the most common primary brain tumors.
  • Despite intensive clinical investigation and many novel therapeutic approaches, treatment for most primary brain tumors remains inadequate.
  • Surgery and radiation remain the primary modalities of therapy for malignant brain tumors.
  • In addition to this encouraging progress, recent experience has shown that selected malignant brain tumors--for example, anaplastic oligodendrogliomas, primary central nervous system lymphomas, medulloblastomas, and intracranial germ cell tumors--are often highly responsive to chemotherapy.
  • Molecular genetic studies are becoming indispensable aids in the diagnosis and treatment of the malignant gliomas.
  • For example, we have learned that allelic loss of chromosome 1p is a significant predictor of chemosensitivity, whereas combined loss of chromosomes 1p and 19q is a strong predictor of chemosensitivity, progression-free survival, and overall survival in patients with anaplastic oligodendroglioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1987 Jul;56(1):89-90 [3620320.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):188-95 [8027800.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):635-43 [1548527.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]
  • [Cites] Neurosurgery. 1993 Mar;32(3):365-70; discussion 371 [8455760.001]
  • [Cites] Oncology (Williston Park). 1995 Jan;9(1):63-71; discussion 71, 75-6, 78 [7718442.001]
  • [Cites] Radiother Oncol. 2001 May;59(2):127-37 [11325440.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2449-55 [11331324.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):153-60 [12816721.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):9-17 [1572835.001]
  • [Cites] Arch Neurol. 2005 Oct;62(10):1595-600 [16216945.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Trends Genet. 1995 Oct;11(10):412-5 [7482768.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] Ann Neurol. 1988 Apr;23(4):360-4 [3382171.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1561-7 [9552066.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1580-90 [1875220.001]
  • [Cites] J Neurooncol. 2006 Sep;79(3):299-305 [16645720.001]
  • [Cites] Radiother Oncol. 2002 Sep;64(3):259-73 [12242114.001]
  • [Cites] J Neurosurg. 1992 May;76(5):741-5 [1564535.001]
  • [Cites] Ann Neurol. 1999 Aug;46(2):183-8 [10443883.001]
  • [Cites] Cancer. 1981 Feb 15;47(4):649-52 [6164465.001]
  • [Cites] Ann Oncol. 2006 Jul;17(7):1141-5 [16603598.001]
  • [Cites] Ann Neurol. 1990 May;27(5):573-4 [2360797.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1044-9 [12637469.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1281-8 [16525183.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):183-8 [16524945.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):602-7 [8814163.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Cancer. 1988 May 1;61(9):1862-6 [3355979.001]
  • [Cites] Acta Neuropathol. 1984;64(4):265-72 [6391068.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1246-52 [16525179.001]
  • [Cites] Neurology. 1994 Sep;44(9):1721-7 [7936304.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Anticancer Res. 1991 Mar-Apr;11(2):719-27 [2064325.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):91-5 [7815084.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Neurosurgery. 1994 Feb;34(2):213-9; discussion 219-20 [8177380.001]
  • (PMID = 17032559.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


38. Shirahata M, Iwao-Koizumi K, Saito S, Ueno N, Oda M, Hashimoto N, Takahashi JA, Kato K: Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis. Clin Cancer Res; 2007 Dec 15;13(24):7341-56
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis.
  • In this study, we focused on anaplastic oligodendroglioma and glioblastoma, which typically follow distinct clinical courses.
  • EXPERIMENTAL DESIGN: The expression of 3,456 genes in 32 patients, 12 and 20 of whom had prognostically distinct anaplastic oligodendroglioma and glioblastoma, respectively, was measured by PCR array.
  • Next to unsupervised methods, we did supervised analysis using a weighted voting algorithm to construct a diagnostic system discriminating anaplastic oligodendroglioma from glioblastoma.
  • Applied to a gene expression data set from a previous study, our model correlated better with outcome than histologic diagnosis, and also displayed 96.6% (28 of 29) consistency with the molecular classification scheme used for these histologically controversial gliomas in the original article.
  • Furthermore, we observed that histologically diagnosed glioblastoma samples that shared anaplastic oligodendroglioma molecular characteristics tended to be associated with longer survival.
  • CONCLUSIONS: Our molecular diagnostic system showed reproducible clinical utility and prognostic ability superior to traditional histopathologic diagnosis for malignant glioma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. Gene Expression Profiling / methods. Glioblastoma / diagnosis. Glioblastoma / genetics. Oligodendroglioma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094416.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. Nakamura M, Shimada K, Nakase H, Konishi N: [Clinicopathological diagnosis of gliomas by genotype analysis]. Brain Nerve; 2009 Jul;61(7):773-80
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological diagnosis of gliomas by genotype analysis].
  • Oligodendroglioma is recognized as a particular subtype of gliomas that shows remarkable response to chemotherapy [procarbazine+CCNU+vincristine (PCV)], making their correct diagnosis important.
  • Loss of heterozygosity (LOH) on chromosomes 1p and 19q is correlated with sensitivity to PCV chemotherapy with increased survival in anaplastic oligodendroglioma cases (WHO grade III).
  • This article suggests that more biological and molecular approaches to brain tumor classification will provide improved means to treat these tumors.
  • [MeSH-major] Genotype. Glioblastoma / diagnosis. Glioblastoma / genetics. Molecular Diagnostic Techniques
  • [MeSH-minor] Antineoplastic Agents, Alkylating. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Dacarbazine / analogs & derivatives. Humans. Lomustine / administration & dosage. Loss of Heterozygosity. Pharmacogenetics. Procarbazine / administration & dosage. Prognosis. Tumor Suppressor Proteins / genetics. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19618854.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; PCV protocol
  • [Number-of-references] 42
  •  go-up   go-down


40. Peria FM, Neder L, Marie SK, Rosemberg S, Oba-Shinjo SM, Colli BO, Gabbai AA, Malheiros SM, Zago MA, Panepucci RA, Moreira-Filho CA, Okamoto OK, Carlotti CG Jr: Pleiotrophin expression in astrocytic and oligodendroglial tumors and it's correlation with histological diagnosis, microvascular density, cellular proliferation and overall survival. J Neurooncol; 2007 Sep;84(3):255-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleiotrophin expression in astrocytic and oligodendroglial tumors and it's correlation with histological diagnosis, microvascular density, cellular proliferation and overall survival.
  • There is evidence that PTN has also a relevant role in primary brain neoplasms and its inactivation could be important to treatment response.
  • Astrocytic and oligodendroglial tumors are the most frequent primary brain neoplasms.
  • Astrocytic tumors are classified as pilocytic astrocytoma (PA), diffuse astrocytoma (DA), anaplastic astrocytoma (AA) and glioblastoma (GBM).
  • Oligodendroglial tumors are classified as oligodendroglioma (O) and anaplastic oligodendroglioma (AO).
  • The aim of the present study was to compare PTN expression, in astrocytomas and oligodendrogliomas and its association with the histological diagnosis, microvascular density, proliferate potential and clinical outcome.
  • The histological diagnosis in accordance with WHO classification was: 13PA, 18DA, 8AA, 15GBM, 16O and 8AO.
  • [MeSH-major] Astrocytoma / pathology. Biomarkers, Tumor / analysis. Brain Neoplasms / pathology. Carrier Proteins / biosynthesis. Cytokines / biosynthesis. Oligodendroglioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] FASEB J. 2004 Aug;18(11):1237-9 [15180956.001]
  • [Cites] Biochem Biophys Res Commun. 2006 May 5;343(2):653-8 [16554021.001]
  • [Cites] Growth Factors. 1994;10(2):89-98 [7520717.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):14153-8 [11809760.001]
  • [Cites] J Neurochem. 2006 Sep;98(5):1497-506 [16923162.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Dec;62(12):1265-75 [14692702.001]
  • [Cites] J Neurochem. 2002 Nov;83(4):747-53 [12421346.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6661-8 [14555979.001]
  • [Cites] J Cutan Pathol. 2005 Feb;32(2):125-30 [15606670.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):127-43 [15013213.001]
  • [Cites] Gene Ther. 2005 Feb;12(4):339-46 [15496960.001]
  • [Cites] J Biol Chem. 2006 Apr 21;281(16):10663-8 [16507572.001]
  • [Cites] Arch Biochem Biophys. 2002 Jan 15;397(2):162-71 [11795867.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Curr Opin Oncol. 2004 Nov;16(6):607-13 [15627025.001]
  • [Cites] J Biol Chem. 1990 Oct 5;265(28):16721-4 [2170351.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2271-8 [16489031.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):26953-64 [15908427.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Dec;44(12):637-43; discussion 644-5 [15684595.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):289-97 [12648577.001]
  • [Cites] Brain Res Dev Brain Res. 2004 Sep 17;152(2):189-97 [15351507.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):35862-8 [12107166.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1468-73 [9776412.001]
  • [Cites] J Biol Chem. 2005 Mar 11;280(10):9180-91 [15632143.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):858-63 [11953815.001]
  • (PMID = 17443289.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Cytokines; 134034-50-7 / pleiotrophin
  •  go-up   go-down


41. Fortin D, Desjardins A, Benko A, Niyonsega T, Boudrias M: Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. Cancer; 2005 Jun 15;103(12):2606-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
  • BACKGROUND: The treatment of malignant brain tumors is hampered by the presence of the blood-brain barrier, which limits chemotherapy penetration to the central nervous system (CNS).
  • The osmotic blood-brain barrier disruption (BBBD) procedure is one such strategy, and has been studied extensively in preclinical and clinical studies.
  • The authors detail their experience so far with the procedure in the context of an open Phase II study in the treatment of malignant brain tumors.
  • METHODS: Patients with histologically proven malignant gliomas, primitive neuroectodermal tumors, primary CNS lymphomas, and metastatic disease to the brain were eligible.
  • The overall median survival times (MST) from treatment initiation for glioblastoma multiforme (GBM), anaplastic oligodendrogliomas, primary CNS lymphomas, and metastases were, respectively, 9.1, 13.9, not reached, and 9.9 months, whereas time to disease progression was 4.1, 9.2, 12.3, and 3.3 months.
  • The MST from diagnosis was 32.2 months for GBM.
  • CONCLUSIONS: These encouraging results prompted the authors to further refine their knowledge of the potential contribution of this procedure in the treatment of brain tumors.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Blood-Brain Barrier / drug effects. Brain Neoplasms / drug therapy. Carboplatin / therapeutic use. Infusions, Intra-Arterial. Methotrexate / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / drug therapy. Astrocytoma / pathology. Child. Disease Progression. Drug Delivery Systems. Female. Glioblastoma / drug therapy. Glioblastoma / pathology. Humans. Lymphoma / drug therapy. Lymphoma / pathology. Male. Middle Aged. Neuroectodermal Tumors, Primitive / drug therapy. Neuroectodermal Tumors, Primitive / pathology. Oligodendroglioma / drug therapy. Oligodendroglioma / pathology. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15880378.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


42. Katoh Y, Katoh M: Comparative genomics on SLIT1, SLIT2, and SLIT3 orthologs. Oncol Rep; 2005 Nov;14(5):1351-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SLIT1 mRNA was expressed in fetal brain, infant brain, anaplastic oligodendroglioma, and Jurkat T cells.
  • [MeSH-minor] Amino Acid Sequence. Animals. Base Sequence. Brain / cytology. Computational Biology. Evolution, Molecular. Genomics. Humans. Intercellular Signaling Peptides and Proteins. Jurkat Cells. Mice. Molecular Sequence Data. Promoter Regions, Genetic. Rats. Sequence Homology. Signal Transduction. Stem Cells. Stomach Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211308.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / Nerve Tissue Proteins; 0 / SLIT1 protein, human; 0 / SLIT3 protein, human; 0 / Slit homolog 2 protein; 0 / Slit3 protein, mouse; 0 / Slit3 protein, rat
  •  go-up   go-down


43. Katoh Y, Katoh M: Comparative genomics on SOX2 orthologs. Oncol Rep; 2005 Sep;14(3):797-800
ZFIN. ZFIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SOX2 mRNA was expressed in ES cells, fetal brain, anaplastic oligodendroglioma, rhabdomyosarcoma, and small cell lung carcinoma.

  • Xenbase. Xenbase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16077994.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / HMGB Proteins; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors; 0 / Sox2 protein, mouse; 0 / Sox2 protein, rat; 0 / Transcription Factors; 0 / Xenopus Proteins; 0 / sox2 protein, Xenopus
  •  go-up   go-down


44. Asano K, Takeda T, Nakano T, Ohkuma H: Correlation of MIB-1 staining index and (201)Tl-SPECT retention index in preoperative evaluation of malignancy of brain tumors. Brain Tumor Pathol; 2010 Apr;27(1):1-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of MIB-1 staining index and (201)Tl-SPECT retention index in preoperative evaluation of malignancy of brain tumors.
  • MIB-1 staining provides a useful index of the malignancy of brain tumors.
  • However, because of the difficulty of evaluating malignancy based on the preoperative imaging findings, we investigated the correlation between the (201)Tl-SPECT retention index (RI) and MIB-1 staining index (MIB-1 SI) to determine the usefulness of RI for preoperative evaluation of the malignancy of brain tumors.
  • The tumors consisted of 16 intraaxial tumors (all gliomas: 9 glioblastomas, 2 anaplastic astrocytomas, 2 anaplastic oligoastrocytomas, 1 oligodendroglioma, and 2 ependymomas), 8 other malignant brain tumors, and 23 extraaxial tumors (10 meningiomas, 7 pituitary adenomas, and 6 schwannomas).
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Ki-67 Antigen / analysis. Preoperative Period. Staining and Labeling. Tomography, Emission-Computed, Single-Photon

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425041.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Radiopharmaceuticals; 0 / Thallium Radioisotopes
  •  go-up   go-down


45. Nafe R, Yan B, Schlote W, Schneider B: Application of different methods for nuclear shape analysis with special reference to the differentiation of brain tumors. Anal Quant Cytol Histol; 2006 Apr;28(2):69-77
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of different methods for nuclear shape analysis with special reference to the differentiation of brain tumors.
  • OBJECTIVE: To study the discriminatory power of different methods designed for nuclear shape analysis with reference to the differentiation and grading of brain tumors and the differentiation between proliferating and nonproliferating nuclei.
  • (1) oligodendrogliomas WHO grade II (n = 13) vs. grade III (n = 11), (2) medulloblastomas WHO grade IV (n = 14) vs. anaplastic ependymomas WHO grade III (n = 12), (3) Ki-67-positive vs. Ki-67-negative tumor cell nuclei in the 14 medulloblastomas.
  • CONCLUSION: Fourier analysis provided an optimal statistical discrimination between different brain tumor entities and between data sets from proliferating and nonproliferating tumor cell nuclei.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16637509.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Hartmann C, von Deimling A: Molecular pathology of oligodendroglial tumors. Recent Results Cancer Res; 2009;171:25-49
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The term oligodendroglioma was created by Bailey, Cushing, and Bucy based on the observation that these tumors share morphological similarities with oligodendrocytes (Bailey and Cushing 1926; Bailey and Bucy 1929).
  • According to the WHO classification of brain tumors, oligodendroglial tumors are separated into oligodendrogliomas WHO grade II (OII), anaplastic oligodendrogliomas WHO grade III (OIII), oligoastrocytomas WHO grade II (OAII), anaplastic oligoastrocytomas WHO grade III (OAIII), and glioblastomas with oligodendroglioma component WHO grade IV (GBMo) (Louis et al. 2007).The perception of oligodendroglial tumors has changed in recent years.
  • The diagnosis of oligodendroglioma or oligoastrocytomas is made much more frequently than 10 years ago.
  • This review focuses on recent developments with impact on the diagnosis and understanding of molecular mechanisms in oligodendroglial tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Oligodendroglioma / genetics. Oligodendroglioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19322536.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Number-of-references] 172
  •  go-up   go-down


47. Alexiou GA, Fotopoulos AD, Papadopoulos A, Kyritsis AP, Polyzoidis KS, Tsiouris S: Evaluation of brain tumor recurrence by (99m)Tc-tetrofosmin SPECT: a prospective pilot study. Ann Nucl Med; 2007 Jul;21(5):293-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of brain tumor recurrence by (99m)Tc-tetrofosmin SPECT: a prospective pilot study.
  • OBJECTIVE: The differentiation between brain tumor recurrence and post-irradiation injury remains an imaging challenge.
  • We assessed (99m)Tc-TF single-photon emission CT (SPECT) in cases where morphologic brain imaging was inconclusive between recurrence and radionecrosis.
  • The initial diagnosis was glioblastoma multiforme (4), anaplastic astrocytoma (1), anaplastic oligodendroglioma (3), grade-II astrocytoma (2), and low-grade oligodendroglioma (1).
  • The remaining 3/11 patients had faint tracer uptake in the suspicious region, compatible with radiation injury; these lesions remained morphologically unaltered in a mean 12-month follow-up period, with no clinical deterioration in the patient's condition, a course strongly favoring the diagnosis of radiation injury.
  • CONCLUSIONS: Metabolic brain imaging by (99m)Tc-TF could offer useful information in the workup of treated brain tumors, where radiomorphologic findings between recurrence and radionecrosis are inconclusive.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Glioma / radionuclide imaging. Organophosphorus Compounds / pharmacology. Organotechnetium Compounds / pharmacology. Radiopharmaceuticals / pharmacology. Recurrence. Tomography, Emission-Computed, Single-Photon / methods
  • [MeSH-minor] Adult. Brain / pathology. Brain / radionuclide imaging. Cell Line, Tumor. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Pilot Projects. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634847.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


48. Xiong NX, Zhao HY, Zhang FC, He ZQ: Negative correlation of Nogo-A with the malignancy of oligodendroglial tumor. Neurosci Bull; 2007 Jan;23(1):41-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The samples used for detection had been diagnosed as oligodendroglial tumors (oligodendroglioma or anaplastic oligodendroglioma).
  • Western-blot analysis also indicated that the gray value of Nogo-A protein band in the oligodendroglioma group was significantly higher than that in the anaplastic oligodendroglioma group.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Myelin Proteins / metabolism. Oligodendroglioma / diagnosis. Oligodendroglioma / metabolism
  • [MeSH-minor] Adult. Down-Regulation / physiology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mitotic Index. Neoplasm Invasiveness / diagnosis. Nogo Proteins. Predictive Value of Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2002 May 1;22(9):3553-67 [11978832.001]
  • [Cites] J Neurosci. 2003 Jul 2;23 (13):5393-406 [12843238.001]
  • [Cites] Oncogene. 2001 Jul 5;20(30):3929-36 [11494121.001]
  • [Cites] J Mol Neurosci. 2005;25(1):1-6 [15781961.001]
  • [Cites] J Cell Physiol. 2003 Aug;196 (2):312-8 [12811824.001]
  • [Cites] Nature. 2000 Jan 27;403(6768):434-9 [10667796.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19280-5 [12639960.001]
  • [Cites] Nature. 2000 Jan 27;403(6768):439-44 [10667797.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):149-58 [9426071.001]
  • [Cites] J Neurochem. 2004 Sep;90(5):1156-62 [15312170.001]
  • [Cites] Oncogene. 2003 Mar 6;22(9):1390-9 [12618765.001]
  • [Cites] Oncogene. 2000 Nov 23;19(50):5736-46 [11126360.001]
  • [Cites] Biochem J. 2005 Oct 15;391(Pt 2):433-40 [16095439.001]
  • [Cites] Oncogene. 2004 Apr 15;23(17):2977-87 [15021917.001]
  • [Cites] Apoptosis. 2003 Jan;8(1):5-9 [12510146.001]
  • (PMID = 17592524.001).
  • [ISSN] 1673-7067
  • [Journal-full-title] Neuroscience bulletin
  • [ISO-abbreviation] Neurosci Bull
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Myelin Proteins; 0 / Nogo Proteins; 0 / RTN4 protein, human
  •  go-up   go-down


49. Sepulveda Sanchez JM, Martinez Montero JC, Diez-Lobato R, Hernandez-Lain A, Cabello A, Ramos A, Gonzalez Leon P, Ricoy Campo JR: Classification of oligodendroglial tumors based on histopathology criteria is a significant predictor of survival--clinical, radiological and pathologic long-term follow-up analysis. Clin Neuropathol; 2009 Jan-Feb;28(1):11-20
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The clinical course of oligodendroglial tumors is variable and there is a lack of consensus with regard to precisely diagnose which minimal criteria are required to make a diagnosis of a high-grade oligodendrial tumor.
  • To make a diagnosis of anaplastic tumor we used reproducible parameters: endothelial proliferation, high cellularity, increased mitotic activity and necrosis.
  • RESULTS: The histologic diagnosis was low-grade oligodendroglioma in 35 patients (43.75%), anaplastic oligodendroglioma in 23 patients (28.75%), low-grade oligoastrocytoma in 11 patients (13.75%) and anaplastic oligoastrocytoma in 11 patients (13.75%).
  • The median overall survival of oligodendroglioma, anaplastic oligodendroglioma, oligoastrocytoma and anaplastic oligoastrocytoma was 148, 105, 47 and 7 months, respectively (p < 0.0001).
  • Multivariate analysis revealed that age, Karnofsky performance status, histological grade and histological diagnosis (oligodendroglioma vs. oligoastrocytoma) were independently associated with survival.
  • [MeSH-major] Brain Neoplasms / classification. Brain Neoplasms / pathology. Oligodendroglioma / classification. Oligodendroglioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Neuropathol. 2009 Mar-Apr;28(2):150
  • (PMID = 19216215.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


50. Zemanová Z, Kramar F, Babická L, Ransdorfová S, Melichercíková J, Hrabal P, Kozler P, Michalová K: Molecular cytogenetic stratification of recurrent oligodendrogliomas: utility of interphase fluorescence in situ hybridization (I-FISH). Folia Biol (Praha); 2006;52(3):71-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In oligodendroglial brain tumours, losses of chromosomal material of the short arm of chromosome 1 and long arm of chromosome 19 have been shown to predict responsiveness to chemotherapy and prolonged patients' survival.
  • Therefore, the correct diagnosis of these genetic alterations in tumours of oligodendroglial origin is particularly important.
  • We examined 16 patients with histologically proved oligodendrogliomas (5x oligodendroglioma, 9x anaplastic oligodendroglioma, 2x anaplastic oligoastrocytoma).
  • A systematic molecular cytogenetic analysis may advance diagnosis, prognostic stratification, and targeted treatment of patients with brain tumours.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. In Situ Hybridization, Fluorescence. Interphase / physiology. Oligodendroglioma / diagnosis. Oligodendroglioma / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089917.001).
  • [ISSN] 0015-5500
  • [Journal-full-title] Folia biologica
  • [ISO-abbreviation] Folia Biol. (Praha)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / DNA Probes
  •  go-up   go-down


51. Bussière M, Hopman W, Day A, Pombo AP, Neves T, Espinosa F: Indicators of functional status for primary malignant brain tumour patients. Can J Neurol Sci; 2005 Feb;32(1):50-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indicators of functional status for primary malignant brain tumour patients.
  • Patients were grouped according to histopathological diagnosis.
  • One hundred and seven patients had a histopathological diagnosis of glioblastoma multiforme, 23 of anaplastic astrocytoma and 13 of anaplastic oligodendroglioma.
  • The anaplastic oligodendroglioma group had lower mortality and maintained better KPS scores over time, as did patients receiving full treatment.
  • The most significant factors associated with time until death included age, severity of comorbidities, pretreatment KPS, presence of confusion, histopathological diagnosis and type of treatment received.
  • [MeSH-major] Brain Neoplasms / physiopathology. Brain Neoplasms / therapy. Glioma / physiopathology. Glioma / therapy. Karnofsky Performance Status

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15825546.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


52. Kuroki K, Sugiyama K, Taguchi H, Yukawa O, Kurokawa M, Kajiwara Y, Usui S, Kurisu K: [Gliomatosis cerebri. Report of two cases]. No Shinkei Geka; 2006 May;34(5):513-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient was diagnosed with gliomatosis cerebri, and surgery and whole brain radiation at 44Gy were performed.
  • A specimen obtained by open biopsy revealed anaplastic oligodendroglioma, which was diagnosed as gliomatosis cerebri.
  • [MeSH-major] Brain Neoplasms / diagnosis. Neoplasms, Neuroepithelial / diagnosis. Oligodendroglioma / diagnosis

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16689395.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


53. White ML, Zhang Y, Kirby P, Ryken TC: Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? AJNR Am J Neuroradiol; 2005 Apr;26(4):784-90
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some authors have even used contrast enhancement as a criterion for their oligodendroglioma grading system.
  • The purpose of our study was to evaluate if tumor contrast enhancement is a specific finding for anaplastic oligodendroglioma.
  • A contrast enhancement ratio (CER), a quantitative criterion, was calculated to assess the difference in degree of enhancement between the low-grade and anaplastic tumors.
  • RESULTS: Contrast enhancement was noted in nine (56%) of 16 low-grade tumors and in five (62%) of eight anaplastic tumors.
  • The CERs were 2.12-40.88 (mean, 20.08) in low-grade tumors and were 3.20-62.52 (mean, 28.73) in anaplastic tumors (P > .05).
  • We believe that the presence or absence of tumor contrast enhancement is not a specific finding for simply discriminating low-grade from anaplastic oligodendrogliomas.
  • [MeSH-major] Brain Neoplasms / pathology. Magnetic Resonance Imaging. Oligodendroglioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15814921.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Benesch M, Siegler N, Hoff Kv, Lassay L, Kropshofer G, Müller H, Sommer C, Rutkowski S, Fleischhack G, Urban C: Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study. Anticancer Drugs; 2009 Oct;20(9):794-9
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study.
  • This retrospective study aimed to evaluate the safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with refractory or recurrent brain tumors.
  • Nineteen heavily pretreated patients (males, n = 14; females, n = 5; median age at diagnosis 8.5 years; range, 1.4-22 years) were given intrathecal liposomal cytarabine on a compassionate use basis for recurrent refractory medulloblastoma (n = 12), mixed germ cell tumor (n = 2), central nervous system primitive neuroectodermal tumors of the pons (n = 1), anaplastic ependymoma (n = 1), anaplastic oligodendroglioma (n = 1), atypical teratoid rhabdoid tumor (n = 1), or rhabdoid papillary meningioma (n = 1).
  • In conclusion, although intrathecal liposomal cytarabine was generally well tolerated, it should be used cautiously and only with dexamethasone prophylaxis in extensively pretreated patients with recurrent brain tumors.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Brain Neoplasms / drug therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617818.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Delayed-Action Preparations; 0 / Liposomes; 04079A1RDZ / Cytarabine
  •  go-up   go-down


55. Iwamoto FM, Reiner AS, Nayak L, Panageas KS, Elkin EB, Abrey LE: Prognosis and patterns of care in elderly patients with glioma. Cancer; 2009 Dec 1;115(23):5534-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The current study was conducted to evaluate the patterns of care and survival of older adults with oligodendroglioma (OLI) and astrocytoma (AST) from a large population-based registry.
  • Patients with a diagnosis of glioblastoma were excluded.
  • The impact of demographic characteristics and comorbidities on the probability of undergoing surgical resection, radiotherapy (RT), and chemotherapy within 6 months of diagnosis was assessed using multivariate logistic regression.
  • RESULTS: A total of 1067 patients (891 with AST and 176 with OLI) were included; the median survival was 9 months for patients with low-grade AST, 4 months for patients with anaplastic AST, 57 months for patients with low-grade OLI, and 9 months for patients with anaplastic OLI.
  • Approximately 54% of patients underwent resection at the time of diagnosis; 66% received RT, and 13% received chemotherapy within 6 months of diagnosis.
  • Patients with anaplastic tumors were treated with resection, RT, and chemotherapy more often than patients with low-grade tumors, and OLI patients received chemotherapy more frequently than AST.
  • CONCLUSIONS: Data from the current study suggested that histologic diagnosis and tumor grade retained significant prognostic value in this elderly AST and OLI population.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Oligodendroglioma / therapy

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • (PMID = 19708033.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


56. Kreiger PA, Okada Y, Simon S, Rorke LB, Louis DN, Golden JA: Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas. Acta Neuropathol; 2005 Apr;109(4):387-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 19 tumors originally diagnosed as oligodendroglioma, 7 were oligodendroglioma, 3 were anaplastic oligodendroglioma, 3 were oligoastrocytoma, and 6 were reclassified.
  • Only one tumor, an anaplastic oligodendroglioma, had 1p loss; none had 19q loss.
  • These results suggest that pediatric oligodendrogliomas arise by molecular alterations distinct from adult oligodendrogliomas, and such molecular alterations do not hold immediate promise as an adjunct to the diagnosis of pediatric oligodendrogliomas.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Oligodendroglioma / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15739101.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA57683
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD20; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Neurofilament Proteins; 0 / Synaptophysin; 0 / Vimentin; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


57. Nutt CL, Betensky RA, Brower MA, Batchelor TT, Louis DN, Stemmer-Rachamimov AO: YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res; 2005 Mar 15;11(6):2258-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we used immunohistochemistry to investigate YKL-40 protein expression in independent sets of glioblastomas and anaplastic oligodendrogliomas to determine whether this single marker can aid classification of these high-grade gliomas.
  • RESULTS AND CONCLUSIONS: Glioblastomas show strikingly more YKL-40 expression than anaplastic oligodendrogliomas.
  • Only 2 of 37 glioblastomas showed completely negative YKL-40 staining in both tumor cells and extracellular matrix, whereas 18 of 29 anaplastic oligodendrogliomas were completely negative in non-microgemistocytic tumor cells and extracellular matrix.
  • Tumor cell staining intensity was also markedly different: 84% of glioblastomas showed strong staining intensities of 2+ or 3+ whereas 76% of anaplastic oligodendrogliomas either did not stain or stained at only 1+.
  • YKL-40 staining provided a better class distinction of glioblastoma versus anaplastic oligodendroglioma than glial fibrillary acidic protein, the current standard immunohistochemical marker used to distinguish diagnostically challenging gliomas.
  • Moreover, a combination of YKL-40 and glial fibrillary acidic protein immunohistochemistry afforded even greater diagnostic accuracy in anaplastic oligodendrogliomas.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Glioblastoma / diagnosis. Glioblastoma / metabolism. Glycoproteins / metabolism. Oligodendroglioma / diagnosis. Oligodendroglioma / metabolism
  • [MeSH-minor] Adipokines. Autoantigens / metabolism. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Diagnosis, Differential. Glial Fibrillary Acidic Protein / analysis. Humans. Immunoenzyme Techniques. Lectins. Neoplasm Staging. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15788675.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 57683
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adipokines; 0 / Autoantigens; 0 / Biomarkers, Tumor; 0 / CHI3L1 protein, human; 0 / Glial Fibrillary Acidic Protein; 0 / Glycoproteins; 0 / Lectins
  •  go-up   go-down


58. Lebrun C, Fontaine D, Bourg V, Ramaioli A, Chanalet S, Vandenbos F, Lonjon M, Fauchon F, Paquis P, Frenay M: Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol; 2007 Apr;14(4):391-8
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on studies relating to anaplastic oligodendroglioma (OG) chemosensitivity and benefit of time to progression or overall survival, chemotherapy for pure OG has been proposed.
  • All patients were symptomatic at presentation and underwent neurosurgical procedure for histological diagnosis.
  • Response was evaluated by clinical assessment and brain magnetic resonance imaging.
  • Twenty-one men and 12 women with a mean age at pathological diagnosis of 46.5 years were studied.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17388986.001).
  • [ISSN] 1468-1331
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; PCV protocol
  •  go-up   go-down


59. Yang T, Pruthi S, Geyer JR, Ojemann JG: MRI changes associated with vigabatrin treatment mimicking tumor progression. Pediatr Blood Cancer; 2010 Dec 1;55(6):1221-3
MedlinePlus Health Information. consumer health - Seizures.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a 5-month-old female who, following resection of an anaplastic oligodendroglioma developed, while treated with vigabatrin for seizures, abnormal DWI and FLAIR MRI signal changes worrisome for tumor progression or recurrence.
  • [MeSH-major] Anticonvulsants / therapeutic use. Brain Neoplasms / diagnosis. Oligodendroglioma / surgery. Seizures / drug therapy. Vigabatrin / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20533524.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; GR120KRT6K / Vigabatrin
  •  go-up   go-down


60. Spampinato MV, Smith JK, Kwock L, Ewend M, Grimme JD, Camacho DL, Castillo M: Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol; 2007 Jan;188(1):204-12
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: PWI and MRS studies of 22 patients with histologically proven oligodendroglioma or oligoastrocytoma (13 low-grade and nine anaplastic tumors) were retrospectively reviewed.
  • The optimal relative cerebral blood volume ratio cutoff value in identification of anaplastic oligodendroglial tumors was 2.14.
  • CONCLUSION: Relative cerebral blood volume measurement and MRS are helpful in differentiating low-grade from anaplastic oligodendroglial tumors.
  • [MeSH-major] Blood Volume. Brain Neoplasms / diagnosis. Diagnosis, Computer-Assisted / methods. Magnetic Resonance Spectroscopy / methods. Oligodendroglioma / diagnosis. Protons

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179366.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


61. Miller CR, Dunham CP, Scheithauer BW, Perry A: Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol; 2006 Dec 1;24(34):5419-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • WHO 2000 grading criteria for high-grade oligodendroglial neoplasms [anaplastic oligoastrocytoma (AOA) and anaplastic oligodendroglioma (AO)] remain subjective, and the existence of grade 4 variants is controversial.
  • PATIENTS AND METHODS: Overall survival (OS) of 1,093 adult patients with a cerebral HGG newly diagnosed between 1990 and 2005 was analyzed by univariate and multivariate models for significance of the following factors: patient age, surgery type, year of diagnosis, endothelial proliferation, necrosis, oligodendroglial histology, treatment center, and chromosome 1p, 19q, 7p (EGFR), and 10q (PTEN) abnormalities by fluorescence in situ hybridization (FISH).
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Oligodendroglioma / genetics. Oligodendroglioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17135643.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32CA009547
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


62. Xiong J, Liu Y, Wang Y, Ke RH, Mao Y, Ye ZR: Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas. Chin Med J (Engl); 2010 Dec;123(24):3566-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to improve the diagnostic criteria and to predict the prognosis of oligodendroglioma patients, the status of chromosome 1p/19q deletion, the methylation of O(6)-methylguanine-DNA methyltransferase (MGMT), and the expression of p53 protein were evaluated and investigated in relation to patients' outcomes.
  • The expression of p53 protein was more frequently observed in patients without a 1p or 19q deletion in anaplastic oligodendrogliomas (P = 0.032, 0.025).
  • CONCLUSION: Detection of chromosome 1p/19q status combined with p53 protein immunohistochemistry might be beneficial to improve the pathological diagnosis and to determine the prognosis of patients with oligodendrogliomas.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosome Deletion. Chromosomes, Human, Pair 19. Oligodendroglioma / genetics. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22166632.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; Chromosome 1, monosomy 1p
  •  go-up   go-down


63. Shirai K, Suzuki Y, Okamoto M, Wakatsuki M, Noda SE, Takahashi T, Ishiuchi S, Hasegawa M, Nakazato Y, Nakano T: Influence of histological subtype on survival after combined therapy of surgery and radiation in WHO grade 3 glioma. J Radiat Res; 2010;51(5):589-94
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • World Health Organization (WHO) grade 3 glioma is one of the common brain tumors and has three main histological subtypes, including anaplastic astrocytoma (AA), anaplastic oligoastrocytoma (AOA) and anaplastic oligodendroglioma (AO).
  • However, most previous studies have considered AOA and AO as one group because of the difficult differential diagnosis between AOA and AO.
  • [MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Glioma / radiotherapy. Oligodendroglioma / radiotherapy

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20921826.001).
  • [ISSN] 1349-9157
  • [Journal-full-title] Journal of radiation research
  • [ISO-abbreviation] J. Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


64. Feiden S, Feiden W: [WHO classification of tumours of the CNS: revised edition of 2007 with critical comments on the typing und grading of common-type diffuse gliomas]. Pathologe; 2008 Nov;29(6):411-21
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, six histological variants of well-known brain tumours have been added, partially because they show different biological behaviour and/or prognosis: pilomyxoid astrocytoma; atypical choroid plexus papilloma; medulloblastoma with extensive nodularity; anaplastic medulloblastoma; extraventricular neurocytoma; non-specific variant of dysembryoplastic neuroepithelial tumour (DNT).
  • Moreover, the typing und grading of common-type diffuse gliomas, as well as the WHO grading system, are critically reviewed, particularly with regard to the prognostically important differential diagnosis of diffuse astrocytomas und oligodendrogliomas.
  • [MeSH-major] Brain Neoplasms / pathology. Central Nervous System Neoplasms / classification. Central Nervous System Neoplasms / pathology. Glioma / classification. Glioma / pathology
  • [MeSH-minor] Astrocytoma / classification. Astrocytoma / pathology. Choroid Neoplasms / classification. Choroid Neoplasms / pathology. Humans. Medulloblastoma / classification. Medulloblastoma / pathology. Oligodendroglioma / classification. Oligodendroglioma / pathology. Papilloma / classification. Papilloma / pathology. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Nov 15;62(10):2152-65 [3179928.001]
  • [Cites] J Neurooncol. 1999 Feb;41(3):267-80 [10359147.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):89-96 [15146346.001]
  • [Cites] Acta Pathol Microbiol Scand. 1950;27(1):51-64 [15406242.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Pathologe. 1998 Jul;19(4):259-68 [9746910.001]
  • [Cites] Brain Pathol. 2007 Jul;17(3):308-13 [17598823.001]
  • [Cites] J Neurosurg. 1999 Dec;91(6):971-7 [10584843.001]
  • [Cites] Pathologe. 2008 Nov;29(6):422-7 [18779965.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1069-73 [17086103.001]
  • [Cites] Brain Pathol. 2007 Jul;17(3):314-8 [17598824.001]
  • [Cites] Brain Pathol. 2007 Jul;17(3):319-24 [17598825.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1949 Feb 2;24(3):71-5 [18111063.001]
  • [Cites] Brain Pathol. 2007 Jul;17(3):304-7 [17598822.001]
  • (PMID = 18820922.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


65. Perry A, Burton SS, Fuller GN, Robinson CA, Palmer CA, Resch L, Bigio EH, Gujrati M, Rosenblum MK: Oligodendroglial neoplasms with ganglioglioma-like maturation: a diagnostic pitfall. Acta Neuropathol; 2010 Aug;120(2):237-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herein, we report seven examples where the primary differential diagnosis was a ganglioglioma with an oligodendroglial component.
  • At presentation, the glial component was oligodendroglioma in six and oligoastrocytoma in one; one was low-grade and six were anaplastic.
  • [MeSH-major] Brain Neoplasms / diagnosis. Ganglioglioma / diagnosis. Oligodendroglioma / diagnosis

  • Genetic Alliance. consumer health - Ganglioglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Acta Neuropathol. 2005 Nov;110(5):520-2 [16222523.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Oct;32(5):461-8 [16972880.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5419-26 [17135643.001]
  • [Cites] Arch Pathol Lab Med. 2007 Feb;131(2):242-51 [17284109.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):124-34 [17259542.001]
  • [Cites] J Neurooncol. 2007 Apr;82(2):199-205 [17039400.001]
  • [Cites] Histopathology. 2007 Jun;50(7):887-96 [17543079.001]
  • [Cites] Semin Ultrasound CT MR. 2008 Feb;29(1):40-6 [18383906.001]
  • [Cites] Brain Pathol. 2008 Jul;18(3):360-9 [18371182.001]
  • [Cites] Brain Pathol. 2008 Jul;18(3):326-37 [18371186.001]
  • [Cites] Mol Cancer. 2008;7:41 [18492260.001]
  • [Cites] Cancer. 2008 Dec 15;113(12):3355-63 [18988291.001]
  • [Cites] J Neurooncol. 2009 Dec;95(3):343-54 [19597701.001]
  • [Cites] Neuro Oncol. 2009 Dec;11(6):737-46 [19224764.001]
  • [Cites] Glia. 2000 Feb 1;29(3):233-45 [10642750.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Pediatr Neurosurg. 2001 Jun;34(6):301-5 [11455230.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):984-93 [11589429.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Apr 1;134(1):71-6 [11996800.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 May;61(5):403-12 [12025943.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Jul;61(7):575-84 [12125736.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Nov;61(11):947-55 [12430711.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:a1-9 [12456321.001]
  • [Cites] Brain Pathol. 2004 Jan;14(1):34-42 [14997935.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):314-22 [15099021.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):89-96 [15146346.001]
  • [Cites] Hum Pathol. 2004 Sep;35(9):1156-9 [15343519.001]
  • [Cites] Histopathology. 1990 Nov;17(5):439-41 [1706300.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] Neuroscience. 1996 Mar;71(2):601-11 [9053811.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):127-31 [8988736.001]
  • [Cites] Acta Neuropathol. 1997 Nov;94(5):436-43 [9386775.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Aug;24(4):302-8 [9775396.001]
  • [Cites] Acta Neuropathol. 1999 May;97(5):481-90 [10334485.001]
  • [Cites] Clin Neuropathol. 2005 Sep-Oct;24(5):225-9 [16167546.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • (PMID = 20464403.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Neurofilament Proteins
  • [Other-IDs] NLM/ PMC2892612
  •  go-up   go-down


66. Ramirez C, Bowman C, Maurage CA, Dubois F, Blond S, Porchet N, Escande F: Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment? Neuro Oncol; 2010 May;12(5):490-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Median age at diagnosis was 45.5 years.
  • Pure oligodendroglioma and temozolomide chemotherapy were correlated with better OS.
  • 10q LOH was correlated with anaplastic grade and 1p19q LOH correlated with pure oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 19 / genetics. Oligodendroglioma / genetics


67. Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE: Salvage temozolomide for prior temozolomide responders. Cancer; 2005 Dec 1;104(11):2473-6
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median age of the patients was 56 years (range, 25-67 yrs) at the time of diagnosis; 9 patients had glioblastoma, 3 had anaplastic astrocytoma, and 2 patients had low-grade oligodendroglioma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Oligodendroglioma / drug therapy. Salvage Therapy / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270316.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


68. Cartalat-Carel S, Chinot O, Honnorat J: [Place of chemotherapy and radiotherapy in the management of oligodendrogliomas]. Neurochirurgie; 2005 Sep;51(3-4 Pt 2):379-92
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty years ago, the discovery of the chemosensitivity of anaplastic oligodendrogliomas considerably boosted interest for these tumors.
  • In spite of difficulties for histological diagnosis, numerous studies on radiotherapy and chemotherapy for oligodendrogliomas appeared these last years.
  • For low grade oligodendrogliomas, radiotherapy delays the anaplastic transformation, but does not modify the overall survival; its indication has to be discussed particularly in the absence of clinical symptoms.
  • Chemotherapy seems to be effective for low grade oligodendrogliomas as well as anaplastic tumors.
  • In anaplastic oligodendrogliomas, in spite of the lack of phase III studies, radiotherapy seems to be effective.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Oligodendroglioma / drug therapy. Oligodendroglioma / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292180.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 55
  •  go-up   go-down


69. Bromberg JE, van den Bent MJ: Oligodendrogliomas: molecular biology and treatment. Oncologist; 2009 Feb;14(2):155-63
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histological diagnosis of oligodendroglial tumors is subject to considerable interobserver variation.
  • The revised 2007 World Health Organization classification of brain tumors no longer accepts the diagnosis "mixed anaplastic oligoastrocytoma" if necrosis is present; these tumors should be considered glioblastomas (perhaps with oligodendroglial features).
  • Currently, the best approach for newly diagnosed anaplastic oligodendroglial tumors is unclear.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / genetics. Oligodendroglioma / drug therapy. Oligodendroglioma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19182242.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 65
  •  go-up   go-down


70. Ducray F, Dutertre G, Ricard D, Gontier E, Idbaih A, Massard C: [Advances in adults' gliomas biology, imaging and treatment]. Bull Cancer; 2010 Jan;97(1):17-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In anaplastic gliomas ongoing studies depend on 1p/19q codeletion status and in glioblastomas on MGMT methylation status.
  • Advanced brain tumor imaging elicits a better identification of gliomas evolutive potential of.
  • In anaplastic gliomas, phase III studies have clarified the respective roles of chemotherapy and radiotherapy.
  • [MeSH-major] Brain Neoplasms. Glioma
  • [MeSH-minor] Adult. Astrocytoma / diagnosis. Astrocytoma / genetics. Astrocytoma / therapy. Combined Modality Therapy / methods. Diagnostic Imaging / methods. Humans. Oligodendroglioma / diagnosis. Oligodendroglioma / genetics. Oligodendroglioma / therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20028650.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Number-of-references] 166
  •  go-up   go-down


71. Sherman JH, Prevedello DM, Shah L, Raghavan P, Pouratian N, Starke RM, Lopes MB, Shaffrey ME, Schiff D: MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status. Acta Neurochir (Wien); 2010 Nov;152(11):1827-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Patients with oligodendrogliomas with allelic loss of chromosomal arm 1p and 19q have been shown, especially with anaplastic oligodendrogliomas, to have both a better initial and long-term response to chemotherapy as well as an improved overall survival.
  • Effective treatment of patients with brain tumors requires accurate diagnostic techniques.
  • Age at diagnosis, gender, tumor grade, chromosomal deletion status, duration of follow-up, and MR imaging characteristics were analyzed; the latter was read by a blinded neuroradiologist.
  • While imaging will never replace definitive tissue diagnosis, imaging characteristics such as tumor size, location, and overlying skull thinning can assist clinicians in assessing patients with oligodendroglial tumors prior to surgical or medical intervention.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Gene Deletion. Genetic Predisposition to Disease / genetics. Oligodendroglioma / genetics. Oligodendroglioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20711790.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


72. Capelle L, Oei P, Teoh H, Hamilton D, Palmer D, Low I, Campbell G: Retrospective review of prognostic factors, including 1p19q deletion, in low-grade oligodendrogliomas and a review of recent published works. J Med Imaging Radiat Oncol; 2009 Jun;53(3):305-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of the present study was to investigate potential prognostic factors in low-grade oligodendrogliomas (LGOs), particularly 1p19q deletion, due to its proven prognostic significance in anaplastic oligodendrogliomas.
  • We carried out a retrospective review of patients with a histological diagnosis of LGO between 1990 and 2000 in Auckland and Wellington, New Zealand.
  • Univariate analysis of potential prognostic factors including 1p19q status, age, tumour size, tumour crossing midline, tumour enhancement, extent of surgery and seizures at diagnosis was carried out.
  • [MeSH-major] Brain Neoplasms. Oligodendroglioma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19624298.001).
  • [ISSN] 1754-9485
  • [Journal-full-title] Journal of medical imaging and radiation oncology
  • [ISO-abbreviation] J Med Imaging Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Australia
  • [Number-of-references] 30
  •  go-up   go-down


73. Roessler K, Gatterbauer B, Becherer A, Paul M, Kletter K, Prayer D, Hoeftberger R, Hainfellner J, Asenbaum S, Knosp E: Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation. Minim Invasive Neurosurg; 2007 Oct;50(5):273-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The objective of this study was to investigate the histological correlate of (11)C-methionine (MET) PET uptake of brain gliomas by image fusion for navigated surgery.
  • CONCLUSION: MET PET image fusion may facilitate the targeting of anaplastic foci in homogeneous MRI non-enhancing gliomas for biopsy, may identify oligodendroglial histology preoperatively as well as characterize biologically active tumor volumes within MRI T(1)/FLAIR tumor areas of candidate patients for resection.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Brain Neoplasms / surgery. Glioma / radionuclide imaging. Glioma / surgery. Neuronavigation / methods. Positron-Emission Tomography / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Carbon Radioisotopes. Child. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted / instrumentation. Image Processing, Computer-Assisted / methods. Male. Methionine / metabolism. Middle Aged. Oligodendroglioma / pathology. Oligodendroglioma / radionuclide imaging. Oligodendroglioma / surgery. Predictive Value of Tests. Preoperative Care / instrumentation. Preoperative Care / methods. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18058643.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; AE28F7PNPL / Methionine
  •  go-up   go-down


74. Shibahara I, Kanamori M, Kumabe T, Endo H, Sonoda Y, Ogawa Y, Watanabe M, Tominaga T: Hemorrhagic onset of pilocytic astrocytoma and pilomyxoid astrocytoma. Brain Tumor Pathol; 2009;26(1):1-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hemorrhagic onset was observed in 4 of 35 (11.4%) patients with pilocytic astrocytoma and pilomyxoid astrocytoma, with higher incidence than in glioblastoma (3.9%), anaplastic oligodendroglioma (7.7%), and anaplastic ependymoma (7.1%).
  • Hemorrhagic onset of pilocytic astrocytoma and pilomyxoid astrocytoma is not as uncommon as was previously thought, so pilocytic astrocytoma or pilomyxoid astrocytoma should be considered in the differential diagnosis of patients with brain tumors manifesting as hemorrhagic onset.
  • [MeSH-major] Astrocytoma / complications. Astrocytoma / pathology. Brain Neoplasms / complications. Brain Neoplasms / pathology. Intracranial Hemorrhages / etiology. Intracranial Hemorrhages / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / pathology. Capillaries / pathology. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging. Male. Middle Aged. Neurofibromatosis 1 / complications. Neurofibromatosis 1 / pathology. Paralysis / etiology. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408090.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


75. Owen CM, Linskey ME: Frame-based stereotaxy in a frameless era: current capabilities, relative role, and the positive- and negative predictive values of blood through the needle. J Neurooncol; 2009 May;93(1):139-49
MedlinePlus Health Information. consumer health - Brain Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnostic accuracy was calculated comparing biopsy diagnosis with final pathology in 11 patients who underwent subsequent surgical resection.
  • Of 18 lesions involving the corpus callosum, 13 (72.2%) were GBM 2 were anaplastic astrocytoma, and 1 each were found to be anaplastic oligodendroglioma, primary central nervous system lymphoma (PCNSL) and tumescent MS.
  • Of 25 multifocal lesions, malignant primary brain tumor was diagnosed in 17 (68%) (11 GBM, 3 PCNSL, 2 anaplastic ologodendroglioma, and 1 anaplastic astrocytoma).
  • CONCLUSIONS: Stereotactic biopsy is an effective, safe and important technique for histologic diagnosis of brain lesions, particularly for multifocal and corpus callosum lesions.
  • [MeSH-major] Biopsy, Needle / methods. Brain Diseases / diagnosis. Brain Diseases / surgery. Neuronavigation
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Comput Aided Surg. 1998;3(2):51-6 [9784952.001]
  • [Cites] Minim Invasive Neurosurg. 2002 Mar;45(1):11-5 [11932818.001]
  • [Cites] Neurosurgery. 2001 Oct;49(4):830-5; discussion 835-7 [11564243.001]
  • [Cites] Br J Neurosurg. 2006 Aug;20(4):222-6 [16954072.001]
  • [Cites] Neurosurgery. 1996 Jan;38(1):170-6; discussion 176-8 [8747966.001]
  • [Cites] Neurosurgery. 2006 Jul;59(1 Suppl 1):ONS146-56; discussion ONS146-56 [16888546.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1985;35:70-4 [3911747.001]
  • [Cites] Ann Surg Oncol. 1994 Sep;1(5):368-72 [7850537.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Nov-Dec;12 (6):1165-75 [1763744.001]
  • [Cites] J Neurosurg. 2006 Feb;104(2):233-7 [16509497.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):31-5 [9647169.001]
  • [Cites] J Neurooncol. 2005 Jun;73(2):173-9 [15981109.001]
  • [Cites] Appl Neurophysiol. 1982;45(4-5):426-30 [7036878.001]
  • [Cites] Surg Neurol. 1984 Sep;22(3):222-30 [6379944.001]
  • [Cites] Surg Neurol. 1980 Oct;14(4):275-83 [7001660.001]
  • [Cites] J Neurosurg. 2005 May;102(5):897-901 [15926716.001]
  • [Cites] Neurosurg Rev. 1994;17 (1):59-66 [8078610.001]
  • [Cites] J Neurooncol. 2006 Jan;76(1):65-70 [16132501.001]
  • [Cites] J Clin Neurosci. 2004 Apr;11(3):263-7 [14975414.001]
  • [Cites] Neurosurgery. 1987 Jun;20(6):930-7 [3302751.001]
  • [Cites] Neurosurgery. 1996 Nov;39(5):907-12; discussion 912-4 [8905744.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):193-200 [11465400.001]
  • [Cites] Br J Neurosurg. 2002 Apr;16(2):110-8 [12046728.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):165-8 [8027795.001]
  • [Cites] Neurol Res. 2005 Jun;27(4):358-62 [15949232.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):370-87 [12186466.001]
  • [Cites] Neurosurgery. 1994 Oct;35(4):682-94; discussion 694-5 [7808612.001]
  • [Cites] J Neurosurg. 2001 Apr;94(4):545-51 [11302651.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):160-8 [10413173.001]
  • [Cites] Neurosurgery. 1983 Mar;12 (3):277-85 [6341870.001]
  • [Cites] Surg Neurol. 2001 Dec;56(6):366-71; discussion 371-2 [11755966.001]
  • [Cites] Acta Neurochir (Wien). 1981;57(3-4):213-34 [6269368.001]
  • (PMID = 19430891.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


76. Laigle-Donadey F, Sanson M: [Pattern of care of high-grade gliomas]. Rev Prat; 2006 Oct 31;56(16):1779-86
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High grade gliomas are the most frequent and malignant primary brain tumours in adults.
  • Surgery is necessary for histological diagnosis.
  • The place of chemotherapy is growing not only for anaplastic oligodendrogliomas, more chemosensitive (particularly when they harbor 1p19q codeletions), but also for glioblastomas patients, which have been shown to benefit from radiotherapy plus concomitant and adjuvant temozolomide.
  • [MeSH-major] Brain Neoplasms / therapy. Glioma / therapy
  • [MeSH-minor] Adrenal Cortex Hormones / administration & dosage. Adrenal Cortex Hormones / therapeutic use. Adult. Age Factors. Aged. Anticonvulsants / therapeutic use. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / therapeutic use. Brain / pathology. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Epilepsy / prevention & control. Forecasting. Genetic Markers. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Humans. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / drug therapy. Oligodendroglioma / drug therapy. Prognosis. Quality of Life. Radiotherapy Dosage. Randomized Controlled Trials as Topic. Survival Analysis. Thromboembolism / prevention & control. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17315503.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anticonvulsants; 0 / Antineoplastic Agents, Alkylating; 0 / Genetic Markers; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 19
  •  go-up   go-down


77. Kurimoto M, Nagai S, Hamada H, Tsuboi Y, Hayashi N, Kubota T, Endo S: Malignant transformation of supratentorial clear cell ependymoma. Neuropathology; 2009 Jun;29(3):299-302
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A brain tumor in the left frontal premotor area was removed and an initial pathological diagnosis of oligodendroglioma was made.
  • The first and second surgical specimens did not contain any ependymal rosettes or pseudorosettes, and thus a diagnosis of oligodendroglioma was made.
  • Thereafter, the recurrent tumors showed anaplastic features such as nuclear pleomorphisms and necrosis with pseudopallisading.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Brain / pathology. Brain / ultrastructure. Diagnosis, Differential. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18647267.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


78. Hilbig A, Barbosa-Coutinho LM, Netto GC, Bleil CB, Toscani NV: [Immunohistochemistry in oligodendrogliomas]. Arq Neuropsiquiatr; 2006 Mar;64(1):67-71
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemistry with glial and neuronal markers may be helpful in differential diagnosis.
  • Ten cases showed anaplastic characteristics.
  • The widespread staining with neuronal marker suggests central neurocytoma, but this diagnosis should not be done with small amount of tissue.
  • [MeSH-major] Antibodies, Neoplasm / analysis. Brain Neoplasms / pathology. Neuroglia / pathology. Oligodendroglioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16622556.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


79. Berbos ZJ, Lee MS, Zaldivar RA, Pambuccian S, Harrison AR: Intravascular lymphoma presenting as an orbital mass lesion: a case report. Orbit; 2010 Apr;29(2):91-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magnetic resonance imaging (MRI) revealed a frontal lobe brain lesion and a right orbital mass.
  • Brain biopsy was interpreted as anaplastic oligodendroglioma.
  • On review of brain histopathology, the diagnosis was revised to CNS intravascular lymphoma.
  • [MeSH-major] Brain Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Orbital Neoplasms / pathology. Vascular Neoplasms / pathology

  • Genetic Alliance. consumer health - Orbital lymphoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20394547.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


80. Jung CS, Foerch C, Schänzer A, Heck A, Plate KH, Seifert V, Steinmetz H, Raabe A, Sitzer M: Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain; 2007 Dec;130(Pt 12):3336-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A serum marker for malignant cerebral astrocytomas could improve both differential diagnosis and clinical management of brain tumour patients.
  • To evaluate whether the serum concentration of glial fibrillary acidic protein (GFAP) may indicate glioblastoma multiforme (GBM) in patients with single supratentorial space-occupying lesions, we prospectively examined 50 consecutive patients with histologically proven GBM, World Health Organization (WHO) grade IV, 14 patients with anaplastic astrocytoma (WHO grade III), 4 patients with anaplastic oligodendroglioma, 13 patients with diffuse astrocytoma (WHO grade II), 17 patients with a single cerebral metastasis and 50 healthy controls.
  • A serum GFAP level of >0.05 microg/l was 76% sensitive and 100% specific for the diagnosis of GBM in patients with a single supratentorial mass lesion in this series.
  • [MeSH-major] Biomarkers, Tumor / blood. Brain Neoplasms / diagnosis. Glial Fibrillary Acidic Protein / blood. Glioblastoma / diagnosis

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998256.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Neoplasm Proteins
  •  go-up   go-down


81. Iwamoto FM, Nicolardi L, Demopoulos A, Barbashina V, Salazar P, Rosenblum M, Hormigo A: Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. J Neurooncol; 2008 Jul;88(3):293-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: There were 113 men and 95 women with a median age at diagnosis of 40.
  • Thirty-eight patients had a low-grade astrocytoma (A2), 58 low-grade oligodendroglioma (O2), 31 low-grade oligoastrocytoma (OA2), 21 anaplastic astrocytoma (A3), 37 anaplastic oligodendroglioma (O3), and 23 had an anaplastic oligoastrocytoma (OA3).
  • [MeSH-major] Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Glioma / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):828-37 [16819324.001]
  • [Cites] Acta Neuropathol. 2004 Jul;108(1):49-56 [15118874.001]
  • [Cites] Int J Cancer. 1994 Apr 15;57(2):172-5 [8157354.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4758-63 [16966689.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1119-28 [15709179.001]
  • [Cites] Ann Neurol. 2005 Jun;57(6):855-65 [15929038.001]
  • [Cites] Genes Chromosomes Cancer. 1992 Nov;5(4):348-56 [1283324.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Ann Neurol. 2005 Sep;58(3):483-7 [16130103.001]
  • [Cites] Ann Neurol. 2005 Aug;58(2):322-6 [16049942.001]
  • (PMID = 18345516.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


82. Oshiro S, Tsugu H, Komatsu F, Abe H, Onishi H, Ohmura T, Iwaasa M, Sakamoto S, Fukushima T: Quantitative assessment of gliomas by proton magnetic resonance spectroscopy. Anticancer Res; 2007 Nov-Dec;27(6A):3757-63
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Eight patients with histologically verified gliomas, comprising 2 cases with glioblastoma multiforme (GBM, grade 4), 5 cases with anaplastic oligodendroglioma (AO, grade 3; high-grade glioma), and 1 case with fibrillary astrocytoma (FA, grade 2; low-grade glioma) were evaluated using the 1H-MRS protocol following conventional MR imaging, diffusion-weighted imaging (DWI), and perfusion-weighted imaging (PWI) preoperatively.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Spectroscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970039.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


83. Belda-Iniesta C, de Castro Carpeño J, Casado Sáenz E, Cejas Guerrero P, Perona R, González Barón M: Molecular biology of malignant gliomas. Clin Transl Oncol; 2006 Sep;8(9):635-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas are the most common primary brain tumours.
  • For example, gliomas of astrocytic origin (astrocytomas) are classified into pilocytic astrocytoma (grade I), astrocytoma (grade II), anaplastic astrocytoma (grade III) and glioblastoma multiforme (GMB) (grade IV).
  • In this regard, a patient diagnosed with an oligodendroglioma totally removed has 10-15 years of potential survival.
  • On the opposite site, patients carrying a glioblastoma multiforme usually die within the first year after the diagnosis is made.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasia. 2005 Jan;7(1):7-16 [15720813.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1033-43 [12937144.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8 [16039986.001]
  • [Cites] Cell. 1995 Dec 15;83(6):993-1000 [8521522.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4088-96 [15899798.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6674-8 [11559533.001]
  • [Cites] Cell Cycle. 2006 Apr;5(7):783-91 [16582634.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):792-800 [16550607.001]
  • [Cites] Cancer Treat Rev. 2004 Apr;30(2):193-204 [15023437.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Nat Genet. 2000 May;25(1):55-7 [10802656.001]
  • [Cites] Int J Cancer. 1995 Aug 9;62(4):386-92 [7635563.001]
  • [Cites] Mol Cancer Ther. 2002 Nov;1(13):1229-36 [12479704.001]
  • [Cites] Cancer Cell. 2003 Apr;3(4):311-6 [12726857.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):269-77 [12086863.001]
  • [Cites] Physiol Genomics. 2001 Feb 07;5(1):21-33 [11161003.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6617-22 [11118044.001]
  • [Cites] Oncogene. 2003 Dec 8;22(56):9030-40 [14663481.001]
  • [Cites] Cancer Res. 2005 May 15;65(10 ):4051-8 [15899794.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):212-21 [14734472.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4183-6 [9331071.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Feb;57(2):122-30 [9600204.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3644-9 [9851971.001]
  • [Cites] Cell. 2004 Apr 16;117(2):211-23 [15084259.001]
  • [Cites] J Neurooncol. 1998 Jan;36(2):123-40 [9525812.001]
  • [Cites] Cancer Res. 1995 May 1;55(9):1941-5 [7728764.001]
  • [Cites] Oncogene. 2001 Mar 1;20(9):1103-9 [11314047.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5804-7 [7954404.001]
  • [Cites] Oncogene. 2004 Jun 3;23 (26):4594-602 [15077177.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6885-91 [11559565.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Oct;11(2):91-6 [7529554.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] J Neuropathol Exp Neurol. 1994 Jan;53(1):11-21 [8301315.001]
  • (PMID = 17005465.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Number-of-references] 36
  •  go-up   go-down


84. Yang SH, Hong YK, Yoon SC, Kim BS, Lee YS, Lee TK, Lee KS, Jeun SS, Kim MC, Park CK: Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma. Oncol Rep; 2007 Jun;17(6):1359-64
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From 1998 to 2004, 39 patients, 22 with glioblastoma (GM), nine with anaplastic astrocytoma (AA), 7 with anaplastic oligodendroglioma (AO) and 1 with anaplastic oligodendro-astrocytoma (AOA) were enrolled in this study.
  • The median interval from the completion of radiotherapy to the diagnosis of necrosis was 19 weeks.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Brain Neoplasms / drug therapy. Glioma / drug therapy

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487391.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


85. Park CK, Lee SH, Han JH, Kim CY, Kim DW, Paek SH, Kim DG, Heo DS, Kim IH, Jung HW: Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy. BMC Cancer; 2009;9:450
Hazardous Substances Data Bank. VINDESINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 133 patients with anaplastic astrocytoma (AA, n = 56), anaplastic oligodendroglioma (AO, n = 67), or anaplastic oligoastrocytoma (AOA, n = 10) were included in the study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Classification / methods. Glioma / diagnosis. Glioma / therapy. Neoplasm Staging / methods. Radiotherapy

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1169-76 [18938045.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1063-71 [12569607.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):227-35 [15279715.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):4002-6 [8508366.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Neurology. 1994 Aug;44(8):1479-83 [8058153.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1018-34; discussion 1034-5 [7885546.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51 [9128946.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):51-5 [9422557.001]
  • [Cites] Jpn J Clin Oncol. 2006 Apr;36(4):193-6 [16611661.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2563-9 [16735709.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5419-26 [17135643.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):295-303 [17001519.001]
  • [Cites] J Neurosurg. 2007 Apr;106(4):575-81 [17432706.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):72-80 [17478095.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Neurol Clin. 2007 Nov;25(4):1089-109, ix-x [17964027.001]
  • [Cites] Brain Pathol. 2008 Jul;18(3):307-16 [18532929.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • (PMID = 20017960.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine; PCV regimen
  • [Other-IDs] NLM/ PMC2806410
  •  go-up   go-down


86. Adamek D, Dec M, Sobol G, Urbanowicz B, Jaworski M: Giant cell ependymoma: a case report. Clin Neurol Neurosurg; 2008 Feb;110(2):176-81
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As a result the diagnosis of GCE was established.
  • This type of neoplasm necessitates, at least in theory, differentiation with anaplastic oligodendroglioma, clear cell ependymoma, pleomorphic xanthoastrocytoma, giant cell glioblastoma, and subependymal giant cell astrocytoma.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology. Lateral Ventricles

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006220.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


87. Atkinson M, Juhász C, Shah J, Guo X, Kupsky W, Fuerst D, Johnson R, Watson C: Paradoxical imaging findings in cerebral gliomas. J Neurol Sci; 2008 Jun 15;269(1-2):180-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Postoperative histopathology was consistent with an oligodendroglioma (grade II) without anaplastic features.
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / diagnosis. Glioma / complications. Glioma / diagnosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18255100.001).
  • [ISSN] 0022-510X
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


88. Massimino M, Gandola L, Luksch R, Spreafico F, Riva D, Solero C, Giangaspero F, Locatelli F, Podda M, Bozzi F, Pignoli E, Collini P, Cefalo G, Zecca M, Casanova M, Ferrari A, Terenziani M, Meazza C, Polastri D, Scaramuzza D, Ravagnani F, Fossati-Bellani F: Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma. Neuro Oncol; 2005 Jan;7(1):41-8
Hazardous Substances Data Bank. THIO-TEPA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologies were glioblastoma multiforme in 10, anaplastic astrocytoma in nine, and anaplastic oligodendroglioma in two; sites of origin were supratentorial areas in 17, spine in two, and posterior fossa in two.
  • Of the 21 patients, 12 have died (10 after relapse, with a median time to progression for the whole series of 14 months; one with intratumoral bleeding at 40 months after diagnosis; and one affected by Turcot syndrome for duodenal cancer relapse).
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Glioma / therapy. Thiotepa / therapeutic use

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 1996 Dec;18 Suppl 3:S1-5 [8971398.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2495-503 [8823328.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40(1):72-4 [9137533.001]
  • [Cites] Anticancer Res. 1997 May-Jun;17(3C):2073-7 [9216666.001]
  • [Cites] Ann Genet. 1997;40(2):78-91 [9259954.001]
  • [Cites] Med Pediatr Oncol. 1997 Dec;29(6):553-9 [9324343.001]
  • [Cites] Med Pediatr Oncol. 1998 Feb;30(2):75-80 [9403013.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):210-21 [9440745.001]
  • [Cites] Childs Nerv Syst. 1997 Nov-Dec;13(11-12):572-7 [9454971.001]
  • [Cites] J Natl Cancer Inst. 1998 Apr 15;90(8):606-11 [9554443.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):52-9 [9647172.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2486-93 [9667268.001]
  • [Cites] Klin Padiatr. 1998 Jul-Aug;210(4):227-33 [9743957.001]
  • [Cites] Bone Marrow Transplant. 1998 Oct;22(7):661-7 [9818693.001]
  • [Cites] Med Pediatr Oncol. 1998 Dec;31(6):483-90 [9835900.001]
  • [Cites] Med Pediatr Oncol. 1999 Aug;33(2):83-7 [10398181.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2117-23 [10570440.001]
  • [Cites] Childs Nerv Syst. 1999 Nov;15(11-12):786-8 [10603023.001]
  • [Cites] Med Pediatr Oncol. 2000 Feb;34(2):147-50 [10657880.001]
  • [Cites] Childs Nerv Syst. 2000 Jan;16(1):15-20 [10672424.001]
  • [Cites] Bone Marrow Transplant. 2000 Jul;26(2):153-60 [10918425.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):264-71 [11815986.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):420-7 [11832530.001]
  • [Cites] Eur J Cancer. 2002 Apr;38(6):815-9 [11937316.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3569-72 [12552957.001]
  • [Cites] Neurosurgery. 1987 Mar;20(3):416-20 [3574617.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1221-31 [3040919.001]
  • [Cites] Cancer Res. 1989 Feb 1;49(3):736-41 [2491958.001]
  • [Cites] J Neurooncol. 1989 May;7(1):5-11 [2754456.001]
  • [Cites] J Neurooncol. 1989 Jul;7(2):165-77 [2550594.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):583-8 [2319317.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2771-8 [2160318.001]
  • [Cites] Bone Marrow Transplant. 1992 Apr;9(4):227-33 [1534708.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):112-8 [8478137.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1458-65 [8336185.001]
  • [Cites] Med Pediatr Oncol. 1994;23(5):428-36 [8084310.001]
  • [Cites] Med Pediatr Oncol. 1995 Feb;24(2):104-8 [7990757.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Eur J Cancer. 1997 Jan;33(1):91-5 [9071906.001]
  • (PMID = 15701281.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 905Z5W3GKH / Thiotepa
  • [Other-IDs] NLM/ PMC1871624
  •  go-up   go-down


89. Evans RW: Thunderclap headache associated with a nonhemorrhagic anaplastic oligodendroglioma. MedGenMed; 2007;9(3):26
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thunderclap headache associated with a nonhemorrhagic anaplastic oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Oligodendroglioma / diagnosis. Temporal Lobe

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurol Clin. 2004 Feb;22(1):133-49 [15062531.001]
  • [Cites] Lancet. 1986 Nov 29;2(8518):1247-8 [2878133.001]
  • [Cites] Lancet Neurol. 2006 Jul;5(7):621-31 [16781992.001]
  • [Cites] Headache. 2006 Mar;46(3):517-20 [16618275.001]
  • [Cites] Headache. 2006 Mar;46(3):520-2 [16618276.001]
  • [Cites] Neurol Sci. 2004 Oct;25 Suppl 3:S143-7 [15549525.001]
  • (PMID = 18092032.001).
  • [ISSN] 1531-0132
  • [Journal-full-title] MedGenMed : Medscape general medicine
  • [ISO-abbreviation] MedGenMed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2100098
  •  go-up   go-down






Advertisement